중앙대학교광명병원 | 산부인과 김병기 의료진 프로필(부인암(자궁경부암, 난소암, 자궁내막암), 부인암 재발, 난치성부인암(자궁육종, 투명세포암, 암육종), 가임력보존 부인암치료, 난소종양, 자궁경부 상피내암, 타목시펜 복용환자의 자궁내막 검진, 유전성 부인암(유방, 난소암 증후군, 린치증후군))

김병기

산부인과

전문분야 :

부인암(자궁경부암, 난소암, 자궁내막암), 부인암 재발, 난치성부인암(자궁육종, 투명세포암, 암육종), 가임력보존 부인암치료, 난소종양, 자궁경부 상피내암, 타목시펜 복용환자의 자궁내막 검진, 유전성 부인암(유방, 난소암 증후군, 린치증후군)

진료예약

학력

서울대학교 대학원 의학박사
서울대학교 대학원 의학석사
서울대학교 의과대학

경력 및 연수

중앙대학교광명병원 산부인과 석좌교수
삼성서울병원 암병원 부인암센터 교수
성균관대학교 의과대학 산부인과학교실 교수
삼성서울병원 산부인과 전문의
미국 임상암학회 회원 (American Society of Clinical Oncology, ASCO)
미국암학회(American Association for Cancer Research, AACR) 회원
국제 부인암학회(International Gynecological Cancer Society, ISGC) 회원
삼성서울병원 암병원 부인암센터장
성균관대학교 의과대학 산부인과학교실 주임교수 및 삼성서울병원 산부인과장
성균관대학교 의과대학 산부인과학교실 부교수
성균관대학교 의과대학 산부인과학교실 임상부교수
원자력병원 산부인과 4과 과장
미국 국립암센터(National Cancer Institute) 초빙연구원
서울대학교병원 부인과 전임의
산부인과 전문의
서울대학교병원 산부인과 전공의
서울대학교병원 인턴

학회활동

수상내역

2008 : 대한산부인과학회 학술상
2007 : BMS 학술상 (대한부인종양학회)
2002 : 대한부인종양학회 학술상
2024: 일본부인종양학회 명예회원

논문 및 저서

1. Kim KH, Lee BH, Do YS, Chin SY, Park SY, Kim BG, Jang JJ. Stage IIb cervical carcinoma: MR evaluation of effect of intraarterial chemotherapy. Radiology 192: 61-66, 1994.

2. Lee JH, Kang YS, Koh JW, Park SY, Kim BG, Lee ED, Lee KH, Park KB, Seo YL. p53 gene mutation is rare in human cervical carcinomas with positive HPV sequences. Int J Gynecol Cancer 4:371-8, 1994.

3. Park SY, Kang YS, Kim BG, Lee SH, Lee ED, Lee KH, Park KB. Loss of heterozygosity on the short arm of chromosome 17 in uterine cervical carcinomas. Cancer Genet Cytogenet 79:74-8, 1995.

4. Lee JH, Kang YS, Kim BG, Park SY, Lee ED, Lee KH, Park KB. Expression of CD44 adhesion molecule in primary and metastatic gynecoogical malignancies and their cell lines. Int J Gynecol Cancer 5:193-9, 1995.

5. Park SY, Kim BG, Kim JH, Lee JH, Lee ED, Lee KH, Park KB, Lee BH, Kim KH. Phase I/II Study of Neoadjuvant Intraarterial Chemotherapy with Mitomycin-C, Vincristine, and Cisplatin in Patients with Stage IIb Bulky Cervical Carcinoma. Cancer 76:815-23, 1995.

6. Lee JH, Kang YS, Park SY, Kim BG, Lee ED, Lee KH, Park KB, Kavanagh JJ, Wharton JT. p53 mutation in epithelial carcinoma and borderline ovarian tumor. Cancer Genet Cytogent 85:43-50, 1995.

7. Hong SI, Park IC, Son YS, Lee SH, Kim BG, Lee JI, Lee TW, Kook YH, Min YI, Hong WS. Expression of urokinase-type plasminogen activator, its receptor, and its inhibitor in gastric adenocarcinoma tissues. J Korean Med Sci 11:33-37, 1996.

8. Kang SB, Kim BG, Song YS, Lee HP. Clinical utility of calculated creatinine clearance as a guide to chemotherapy in patients with gynecologic malignancies. J Obstet Gynecol Res 22: 67-71, 1996.

9. Kim BG, Kim JH, Park SY, Lee JH, Lee ED, Lee KH, Park KB, Lee BH, Kim KH. Relationship between squamous cell carcinoma antigen levels and tumor volumes in patients with cervical carcinomas undergoing neoadjuvant chemotherapy. Gynecol Oncol 63: 105-113, 1996.

10. Choi H, Park CS, Kim BG, Cho JW, Park JB, Bae YS, Bae DS. Creatine kinase B is a target molecule of reactive oxygen species in cervical cancer. Mol Cells 12:412-417, 2001.

11. Roh CR, Lee JW, Kang BH, Yang SH, Kim BG, Bae DS, Kim JH, Lee JH. Differential expression of Fas and Fas ligand in human placenta. J Korean Med Sci 17:213-216, 2002.

12. J.W. Lee, B.G. Kim, S.J. Lee S.H. Lee, C.S. Park, J.H. Lee, S.J. Huh, D.S. Bae. Preliminary results of consolidation chemotherapy following concurrent chemoradiation after radical surgery in high-risk early-sstage carcinoma of the uterine cervix. Clin Oncol (R Coll Radiol). 2005 Sep;17(6):412-7.

13. Lee JW, Lee SJ, Seo JW, Song YS, Ahn GH, Park CS, Lee JH, Kim BG, Bae DS. Increased Expression of Claudin-1 and Claudin-7 During the Progression of Cervical Neoplasia. Gynecol Oncol 97:53-59, 2005.

14. Park W, Park YJ, Huh SJ, Kim BG, Bae DS, Lee JH, Kim BH, Choi JY, Ahn YC, Lim DH. The usefulness of MRI and PET imaging for the detection of parametrial involvement and lymph node metastasis in patients with cervical cancer. Jpn J Clin Oncol. 2005 May;35(5):260-4.

15. Young Min Chung, Byoung-Gie Kim, Chang-Soo Park, Seung-Jae Huh, Jingook Kim, Jong Kuk Park, Seon Mi Cho, Jun Suk Kim, Young Do Yoo and Duk-Soo Bae. Increased Expression of ICAM-3 Is Associated with Radiation Resistance in Cervical Cancer. Int J Cancer. 2005 Nov 1;117(2):194-201.

16. E.J. Lee, G. Kong, S.H. Lee, S.B. Rho, C.S. Park, B.G. Kim, D.S. Bae, J.J. Kavanagh, J.H. Lee. Profiling of differentially expressed genes in human uterine leiomyomas. Int J Gynecol Cancer 15(1):146-54, January 2005.

17. Sun-Joo Lee, Kyung Lan Jung, Jeong-Won Lee, Sang Yong Song*, Byoung-Gie Kim, Je-Ho Lee, Chang-Soo Park, Duk-Soo Bae. Analyses of Atypical Squamous Cells (ASC) Refined by the 2001 Bethesda System: The distribution and clinical significance of follow-up management. Int J Gynecol Cancer 2006 Mar-Apr;16(2):664-9.

18. Lee JW, Song SY, Choi J, Lee SJ, Kim BG, Park CS, Lee JH, Lin CY, Dickson RB, Bae DS. Increased Expression of Matriptase Is Associated with Histopathologic Grades of Cervical Neoplasia. Human Pathol 2005 Jun;36(6):626-33.

19. Jeong-Won Lee, Chul Jung Kim, Ji Eun Lee, Sun-Joo Lee, Byoung-Gie Kim, Je-Ho Lee, Duk-Soo Bae, Chang-Soo Park Selected Adnexal Cystic Masses in Postmenopausal Women Can be Safely Managed by Laparoscopy. J Korean Med Sci. 2005 Jun;20(3):468-72.

20. Sun-Joo Lee, Jeong-Won Lee, Jung Ae Min, Chang-Soo Park, Byoung-Gie Kim, Je-Ho Lee, Duk-Soo Bae, A Pilot Study of Three Cycle-Consolidation Chemotherapy with Paclitaxel and Platinum in Epithelial Ovarian Cancer. Int J Gynecol Cancer 2006 Jan-Feb;16(1):95-100.

21. Chel-Hoon Choi, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, Je-Ho Lee, Duk-Soo Bae. Phase II study of neoadjuvant chemotherapy with mitomycin-c, vincristine and cisplatin (MVC) in patients with stages IB2-IIB cervical carcinoma. Gynecol Oncol. 2007 Jan;104(1):64-9.

22. Dong-Suk Choi, Jeong-Won Lee, Sun-Joo Lee, Chel-Hoon Choi, Tae-Joong Kim, Je-Ho Lee, Geung-Hwan Ahn, Duk-Soo Bae, Byoung-Gie Kim. Squamous cell carcinoma with sarcomatoid features of the vulva: A case report and review of literature. Gynecol Oncol. 2006 Oct;103(1):363-7.

23. Choi CH, Kim TJ, Lee SJ, Lee JW, Kim BG, Lee JH, Bae DS. Salvage chemotherapy with a combination of paclitaxel, ifosfamide, and cisplatin for the patients with recurrent carcinoma of the uterine cervix. Int J Gynecol Cancer. 2006 May-Jun;16(3):1157-64.

24. Kim TJ, Rho SB, Choi YL, Choi CH, Lee JW, Bae DS, Ahn GH, Lee JH, Kim BG. High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis. Hum Pathol. 2006 Jul;37(7):906-13.

25. Kim TJ, Lee JW, Song SY, Choi JJ, Choi CH, Kim BG, Lee JH, Bae DS. Increased expression of pAKT is associated with radiation resistance in cervical cancer. Br J Cancer. 2006 Jun 5;94(11):1678-82.

26. Choi CH, Rho CR, Kim TJ, Choi YL, Lee JW, Kim BG, Lee JH, Bae DS. Expression of CD44 adhesion molecules on human placentae. Eur J Obstet Gynecol Reprod Biol. 2006 Sep-Oct;128(1-2):243-7.

27. Kim TJ, Lee KM, Choi CH, Lee JW, Lee JH, Bae DS, Kim BG. Germline mutations of BRCA1 in two Korean hereditary breast/ovarian cancer families. Oncol Rep. 2006 Mar;15(3):565-9.

28. Lee SJ, Kim BG, Lee JW, Park CS, Lee JH, Bae DS. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. J Obstet Gynaecol Res. 2006 Feb;32(1):99-106.

29. Lee JW, Song SY, Choi JJ, Choi CH, Kim TJ, Kim J, Lee JH, Kim BG, Bae DS. Decreased galectin-3 expression during the progression of cervical neoplasia. J Cancer Res Clin Oncol. 2006 Apr;132(4):241-7.

30. Lee JW, Choi JJ, Lee KM, Choi CH, Kim TJ, Lee JH, Kim BG, Ahn G, Song SY, Bae DS. eIF-4E expression is associated with histopathologic grades in cervical neoplasia. Hum Pathol. 2005 Nov;36(11):1197-203.

31. Yang SY, Lee JW, Kim WS, Jung KL, Lee SJ, Lee JH, Bae DS, Kim BG. Adenoid cystic carcinoma of the Bartholin's gland: report of two cases and review of the literature.Gynecol Oncol. 2006 Feb;100(2):422-5.

32. Nam H, Park W, Huh SJ, Bae DS, Kim BG, Lee JH, Lee JW, Lim DH, Han Y, Park HC, Ahn YC. The prognostic significance of tumor volume regression during radiotherapy and concurrent chemoradiotherapy for cervical cancer using MRI. Gynecol Oncol. 2007 107:320-325

33. Kim WY, Lee JW, Choi JJ, Choi CH, Kim TJ, Kim BG, Song SY, Bae DS. Increased expression of Toll-like receptor 5 during progression of cervical neoplasia. Int J Gynecol Cancer. 2007 Jun 22; [Epub ahead of print]

34. Choi CH, Lee KM, Choi JJ, Kim TJ, Kim WY, Lee JW, Lee SJ, Lee JH, Bae DS, Kim BG. Hypermethylation and loss of heterozygosity of tumor suppressor genes on chromosome 3p in cervical cancer. Cancer Lett. 2007 Sep 18;255(1):26-33.

35. Kim TJ, Song S, Kim CK, Kim WY, Choi CH, Lee JH, Lee JW, Bae DS, Kim BG. Prognostic factors associated with brain metastases from epithelial ovarian carcinoma. Int J Gynecol Cancer. 2007 Apr 18; [Epub ahead of print]

36. Lee JW, Choi JJ, Seo ES, Kim MJ, Kim WY, Choi CH, Kim TJ, Kim BG, Song SY, Bae DS. Increased toll-like receptor 9 expression in cervical neoplasia. Mol Carcinog. 2007 Apr 17; [Epub ahead of print]

37. Choi CH, Kim TJ, Kim WY, Ahn GH, Lee JW, Kim BG, Lee JH, Bae DS. Papillary serous carcinoma in ovaries of normal size: a clinicopathologic study of 20 cases and comparison with extraovarian peritoneal papillary serous carcinoma. Gynecol Oncol. 2007 Jun;105(3):762-8.

38. Choi CH, Lee JW, Kim TJ, Kim WY, Nam HR, Kim BG, Huh SJ, Lee JH, Bae DS. Phase II study of consolidation chemotherapy after concurrent chemoradiation in cervical cancer: preliminary results. Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):817-22.

39. Lee SJ, Choi YL, Lee EJ, Kim BG, Bae DS, Ahn GH, Lee JH. Increased expression of calpain 6 in uterine sarcomas and carcinosarcomas: an immunohistochemical analysis. Int J Gynecol Cancer. 2007 Jan-Feb;17(1):248-53.

40. Kim TJ, Choi JJ, Kim WY, Choi CH, Lee JW, Bae DS, Son DS, Kim J, Park BK, Ahn GH, Cho EY, Kim BG. Gene expression profiling for the prediction of lymph node metastasis in patient with cervical cancer. Cancer Sci. 2007 Nov 6; [Epub ahead of print].

41. Oh DR.,* Huh SJ,.,* Nam HR,*Park W,*Han YY,* Lim DH,* Ahn YC, Lee JW, Kim BG, Bae DS,and Lee JH. Pelvic insufficiency fracture after pelvic radiotherapy for cervical cancer: analysis of risk factors. Int J Radiat Oncol Biol Phys. 2007 [Epub ahead of print]

42. Kim CK, Park BK, Choi JY, Kim BG, Han H. Detection of Recurrent Ovarian Cancer at MRI: Comparison With Integrated PET/CT. J Comput Assist Tomogr. 2007 November/December;31(6):868-875.

43. Choi CH, Kang H, Kim WY, Kim TJ, Lee JW, Huh SJ, Lee JH, Kim BG, Bae DS. Prognostic Value of Baseline Lymphocyte Count in Cervical Carcinoma Treated with Concurrent Chemoradiation. Int J Radiat Oncol Biol Phys. 2007 Nov 23; [Epub ahead of print]

44. Kim WY, Lee JW, Choi CH, Kang H, Kim TJ, Kim BG, Lee JH, Bae DS. Low-grade endometrial stromal sarcoma: a single center's experience with 22 cases. Int J Gynecol Cancer. 2007 Dec 27 [Epub ahead of print]

45. Lee JW, Choi CH, Choi JJ, Park YA, Kim SJ, Hwang SY, Kim WY, Kim TJ, Lee JH, Kim BG,Bae DS. Altered MicroRNA Expression in Cervical Carcinomas. Clin Cancer Res. 2008 May 1;14(9):2535-42.

46. Kang H, Kim TJ, Kim WY, Choi CH, Lee JW, Kim BG, Bae DS. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor. Gynecol Oncol. 2008 Jul 23. [Epub ahead of print]

47. Lee JK, Song SH, Kim I, Lee KH, Kim BG, Kim JW, Kim YT, Park SY, Cha MS, Kang SB. Retrospective multicenter study of a clinicopathologic analysis of pseudomyxoma peritonei associated with ovarian tumors (KGOG 3005). Int J Gynecol Cancer. 2008 Jan 31. [Epub ahead of print]

48. Lee SJ, Kim BG, Choi YL, Lee JW. Increased expression of calpain 6 during the progression of uterine cervical neoplasia: immunohistochemical analysis. Oncol Rep. 2008 Apr;19(4):859-63.

49. Choi CH, Song SY, Choi JJ, Park YA, Kang H, Kim TJ, Lee JW, Kim BG, Lee JH, Bae DS. Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy. BMC Cancer. 2008 Oct 11;8:295 .

50. Kim HS, Kim TJ, Chung HH, Kim JW, Kim BG, Park NH, Song YS, Bae DS, Kang SB. In vitro extreme drug resistance assay to taxanes or platinum compounds for the prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study. J Cancer Res Clin Oncol. 2009 May 16. [Epub ahead of print].

51. Kang H, Kim TJ, Lee YY, Choi CH, Lee JW, Bae DS, Kim BG. Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: Results of a single-institutional phase II study. Gynecol Oncol. 2009 May 13. [Epub ahead of print].

52. Lee SJ, Kim WY, Lee JW, Kim HS, Choi YL, Ahn GH, Lee JH, Kim BG, Bae DS. Conization using electrosurgical conization and cold coagulation for international federation of gynecology and obstetrics stage IA1 squamous cell carcinomas of the uterine cervix. Int J Gynecol Cancer. 2009 Apr;19(3):407-11.

53. Lee KH, Lee IH, Kim BG, Nam JH, Kim WK, Kang SB, Ryu SY, Cho CH, Choi HS, Kim KT; Korean Gynecologic Oncology Group. Clinicopathologic characteristics of malignant germ cell tumors in the ovaries of korean women: a Korean Gynecologic Oncology Group Study. Int J Gynecol Cancer. 2009 Jan-Feb;19(1):84-7.

54. Shin DW, Ahn E, Kim YM, Kang S, Kim BG, Seong SJ, Cha SD, Park CY, Yun YH. Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer quality of life questionnaire cervical cancer module. Oncology. 2009;76(3):190-8. Epub 2009 Feb 11..

55. Ryu SY, Park SI, Nam BH, Kim I, Yoo CW, Nam JH, Lee KH, Cho CH, Kim JH, Park SY, Kim BG, Kang SB. Prognostic significance of histological grade in clear-cell carcinoma of the ovary: a retrospective study of Korean Gynecologic Oncology Group. Ann Oncol. 2009 Feb 4. [Epub ahead of print]

56. Lee TS, Kim JW, Kim TJ, Cho CH, Ryu SY, Ryu HS, Kim BG, Lee KH, Kim YM, Kang SB; Korean Gynecologic Oncology Group. Ovarian preservation during the surgical treatment of early stage endometrial cancer: a nation-wide study conducted by the Korean Gynecologic Oncology Group. Gynecol Oncol. 2009 Oct;115(1):26-31. Epub 2009 Jul 26.

57. Lee YY, Choi CH, Kim CJ, Kang H, Kim TJ, Lee JW, Lee JH, Bae DS, Kim BG. The prognostic significance of the SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) of the cervical tumor in PET imaging for early cervical cancer: preliminary results. Gynecol Oncol. 2009 Oct;115(1):65-8. Epub 2009 Jul 15.

58. Lee YY, Kim TJ, Kim CJ, Kang H, Choi CH, Lee JW, Kim BG, Lee JH, Bae DS. Single-port access laparoscopic-assisted vaginal hysterectomy: a novel method with a wound retractor and a glove. J Minim Invasive Gynecol. 2009 Jul-Aug;16(4):450-3. Epub 2009 May 31.

59. Kang MK, Park W, Choi YL, Cho EY, Ahn G, Nam H, Huh SJ, Ahn YC, Lim do H, Oh DR, Bae DS, Kim BG. The effect of cyclooxygenase-2 expression on tumor volume response in patients treated with radiotherapy for uterine cervical cancer. J Korean Med Sci. 2009 Dec;24(6):1170-6. Epub 2009 Nov 9.

60. Yoon G, Kim TJ, Lee YY, Kim CJ, Choi CH, Lee JW, Kim BG, Bae DS. Single-Port Access Subtotal Hysterectomy with Transcervical Morcellation: A Pilot Study. J Minim Invasive Gynecol. 2009 Nov 17. [Epub ahead of print

61. Lee YY, Kim TJ, Choi CH, Lee JW, Kim BG, Bae DS. Factors influencing the choice of laparoscopy or laparotomy in pregnant women with presumptive benign ovarian tumors. Int J Gynaecol Obstet. 2010 Jan;108(1):12-5.

62. Kim TJ, Lee YY, Kim MJ, Kim CJ, Kang H, Choi CH, Lee JW, Kim BG, Bae DS. Single port access laparoscopic adnexal surgery. J Minim Invasive Gynecol. 2009 Sep-Oct;16(5):612-5

63. Kang H, Kim TJ, Choi CH, Lee JW, Lee JH, Bae DS, Kim BG. Phase II study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer. J Korean Med Sci. 2009 Oct;24(5):945-50. Epub 2009 Sep 24.

64. Kim WY, Kim TJ, Kim SE, Lee JW, Lee JH, Kim BG, Bae DS. The role of cytoreductive surgery for non-genital tract metastatic tumors to the ovaries. Eur J Obstet Gynecol Reprod Biol. 2009 Dec 15. [Epub ahead of print]

65. Lee EJ, Kim TJ, Kim DS, Choi CH, Lee JW, Lee JH, Bae DS, Kim BG. p53 alteration independently predicts poor outcomes in patients with endometrial cancer: A clinicopathologic study of 131 cases and literature review. Gynecol Oncol.. [Epub ahead of print]

66. Lee YY, Choi CH, Kim CJ, Song TJ, Kim MK, Kim TJ, Lee JW, Kim BG, Lee JH, Bae DS. Glucose as a prognostic factor in non-diabetic women with locally advanced cervical cancer (IIB-IVA). Gynecol Oncol.. [Epub ahead of print]

67. Song T, Kim TJ, Kim MK, Park H, Kim JS, Lee YY, Kim CJ, Choi CH, Lee JW, Kim BG, Bae DS. Single Port Access Laparoscopic-Assisted Vaginal Hysterectomy for Large Uterus Weighing Exceeding 500 Grams: Technique and Initial Report. J Minim Invasive Gynecol. 2010 May 13. [Epub ahead of print].

68. Choi CH, Lee JS, Kim SR, Lee YY, Kim CJ, Lee JW, Kim TJ, Lee JH, Kim BG, Bae DS. Direct inhibition of eIF4E reduced cell growth in endometrial adenocarcinoma. J Cancer Res Clin Oncol. 2010 May 13. [Epub ahead of print]

69. Lee YY, Kim TJ, Kim CJ, Park HS, Choi CH, Lee JW, Lee JH, Bae DS, Kim BG. Single port access laparoscopic adnexal surgery versus conventional laparoscopic adnexal surgery: a comparison of peri-operative outcomes. Eur J Obstet Gynecol Reprod Biol. 2010 Apr 13. [Epub ahead of print]

70. Lee TS, Kim JW, Kim DY, Kim YT, Lee KH, Kim BG, McMeekin DS. Necessity of radical hysterectomy for endometrial cancer patients with cervical invasion. J Korean Med Sci. 2010 Apr;25(4):552-6. Epub 2010 Mar 19.

71. Yeom SY, Jang HL, Lee SJ, Kim E, Son HJ, Kim BG, Park C. Interaction of testisin with maspin and its impact on invasion and cell death resistance of cervical cancer cells. FEBS Lett. 2010 Apr 16;584(8):1469-75. Epub 2010 Mar 6.

72. Lee DY, Park HJ, Kim BG, Bae DS, Yoon BK, Choi D. Change in the ovarian environment after hysterectomy as assessed by ovarian arterial blood flow indices and serum anti-Müllerian hormone levels. Eur J Obstet Gynecol Reprod Biol. 2010 Mar 6. [Epub ahead of print]

73. Kim TJ, Lee YY, Cha HH, Kim CJ, Choi CH, Lee JW, Bae DS, Lee JH, Kim BG. Single-port-ac cess laparoscopic-assisted vaginal hysterectomy versus conventional laparoscopic-assisted vaginal hysterectomy: a comparison of perioperative outcomes. Surg Endosc. 2010 Feb 23. [Epub ahead of print].

74. Sung CO, Park W, Choi YL, Ahn G, Song SY, Huh SJ, Bae DS, Kim BG, Lee JH. Prognostic significance of CD24 protein expression in patients treated with adjuvant radiotherapy after radical hysterectomy for cervical squamous cell carcinoma. Radiother Oncol. 2010 Feb 12. [Epub ahead of print]

75. Kang S, Kim TJ, Nam BH, Seo SS, Kim BG, Bae DS, Park SY. Preoperative serum CA-125 levels and risk of suboptimal cytoreduction in ovarian cancer: a meta-analysis. J Surg Oncol. 2010 Jan 1;101(1):13-7.

76. Song T, Kim TJ, Kim MK, Park H, Kim JS, Lee YY, Kim CJ, Choi CH, Lee JW, Kim BG,

Bae DS. Single Port Access Laparoscopic-Assisted Vaginal Hysterectomy for Large Uterus Weighing Exceeding 500 Grams: Technique and Initial Report. J Minim Invasive Gynecol. 2010 Jul;17(4):456-460. Epub 2010 May 14.

77. Choi CH, Song SY, Kang H, Lee YY, Kim CJ, Lee JW, Kim TJ, Kim BG, Lee JH, Bae DS. Prognostic significance of p-STAT3 in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy. J Obstet Gynaecol Res. 2010 Apr;36(2):304-10.

78. Lee YY, Kim TJ, Kang H, Choi CH, Lee JW, Kim BG, Bae DS. The use of misoprostol before hysteroscopic surgery in non-pregnant premenopausal women: a randomized comparison of sublingual, oral and vaginal administrations. Hum Reprod. 2010 Aug;25(8):1942-8. Epub 2010 Jun 11.

79. Lee YY, Do IG, Park YA, Choi JJ, Song SY, Kim CJ, Kim MK, Song TJ, Park HS, Choi CH, Kim TJ, Kim BG, Lee JW, Bae DS. Low dynamin 2 expression is associated with tumor invasion and metastasis in invasive squamous cell carcinoma of cervix. Cancer Biol Ther. 2010 Aug;10(4):329-35. Epub 2010 Aug 7.

80. Lee YY, Lee JW, Park HS, Song TJ, Kim MK, Choi CH, Kim TJ, Lee JH, Bae DS, Kim BG. Sequence-dependent hematologic side effects of topotecan and cisplatin in persistent or recurrent cervical cancer. Gynecol Oncol. 2010 Oct;119(1):87-91. Epub 2010 Jun 26.

81. Kim SH, Kang S, Kim YM, Kim BG, Seong SJ, Cha SD, Park CY, Yun YH. Prevalence and predictors of anxiety and depression among cervical cancer survivors in Korea. Int J Gynecol Cancer. 2010 Aug;20(6):1017-24.

82. Lee YY, Choi CH, Kim TJ, Lee JW, Kim BG, Lee JH, Bae DS. A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB-IIA. Gynecol Oncol. 2010 Dec 7. [Epub ahead of print.

83. Kim CJ, Lee JW, Choi JJ, Choi HY, Park YA, Jeon HK, Sung CO, Song SY, Lee YY, Choi CH, Kim TJ, Lee JH, Kim BG, Bae DS. High claudin-7 expression is associated with a poor response to platinum-based chemotherapy in epithelial ovarian carcinoma. Eur J Cancer. 2010 Dec 4. [Epub ahead of print]

84. Choi CH, Lee YY, Song TJ, Park HS, Kim MK, Kim TJ, Lee JW, Lee JH, Bae DS, Kim BG. Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer. Cancer. 2011 May 15;117(10):2104-11. doi: 10.1002/cncr.25710. Epub 2010 Nov 29.

85. Choi CH, Lee YY, Kim MK, Kim TJ, Lee JW, Nam HR, Huh SJ, Lee JH, Bae DS, Kim BG. A Matched-Case Comparison to Explore the Role of Consolidation Chemotherapy After Concurrent Chemoradiation in Cervical Cancer. Int J Radiat Oncol Biol Phys. 2010 Nov 13. [Epub ahead of print]

86. Park HS, Kim TJ, Song T, Kim MK, Lee YY, Choi CH, Lee JW, Kim BG, Bae DS. Single-port access (SPA) laparoscopic surgery in gynecology: a surgeon's experience with an initial 200 cases. Eur J Obstet Gynecol Reprod Biol. 2010 Nov 4. [Epub ahead of print]

87. Kang S, Kim TJ, Seo SS, Kim BG, Bae DS, Park SY. Interaction between preoperative CA-125 level and survival benefit of neoadjuvant chemotherapy in advanced epithelial ovarian cancer. Gynecol Oncol. 2011 Jan;120(1):18-22. Epub 2010 Oct 28.

88. Lee JW, Park YA, Choi JJ, Lee YY, Kim CJ, Choi C, Kim TJ, Lee NW, Kim BG, Bae DS. The expression of the miRNA-200 family in endometrial endometrioid carcinoma. Gynecol Oncol. 2011 Jan;120(1):56-62. Epub 2010 Oct 28.

89. Kim MK, Kim TJ, Sung CO, Choi CH, Lee JW, Kim BG, Bae DS. High expression of mTOR is associated with radiation resistance in cervical cancer. J Gynecol Oncol. 2010 Sep;21(3):181-5. Epub 2010 Sep 28.

90. Song T, Choi CH, Lee YY, Kim TJ, Lee JW, Bae DS, Kim BG. Pediatric borderline ovarian tumors: a retrospective analysis. J Pediatr Surg. 2010 Oct;45(10):1955-60.

91. Choi CH, Lee JS, Kim SR, Kim TJ, Lee JW, Kim BG, Bae DS. Clinical significance of pmTOR expression in endometrioid endometrial carcinoma.Eur J Obstet Gynecol Reprod Biol. 2010 Dec;153(2):207-10. Epub 2010 Aug 21

92. Kim YS, Bae DS, Kim BG, Lee JW, Kim TJ. A faster nonsurgical solution Very large fibroid tumors yielded to a new ablation strategy. Am J Obstet Gynecol. 2011 Sep;205(3):292.e1-5. Epub 2011 Jul 23. No abstract available.

93. Park YA, Lee JW, Choi JJ, Jeon HK, Cho Y, Choi C, Kim TJ, Lee NW, Kim BG, Bae DS. The interactions between MicroRNA-200c and BRD7 in endometrial carcinoma.Gynecol Oncol. 2011 Oct 17. [Epub ahead of print]

94. Lee YY, Choi CH, Sung CO, Do IG, Huh S, Song T, Kim MK, Kim HJ, Kim TJ, Lee JW, Kim BG, Bae DS.Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: Comparison with SCC-Ag level.Gynecol Oncol. 2011 Oct 18. [Epub ahead of print]

95. Ryu JH, Choi CH, Kim TJ, Lee JW, Kim BG, Bae DS.Chemo-resistant choriocarcinoma metastatic to colon cured by low-anterior resection. J Gynecol Oncol. 2011 Sep;22(3):203-6. Epub 2011 Sep 28.

96. Song T, Lee JW, Choi CH, Kim TJ, Bae DS, Sung CO, Song SY, Kim BG. Ploidy and S-phase fraction are correlated with lymphovascular space invasion that is predictive of outcomes in endometrial cancer. Int J Clin Oncol. 2011 Oct 13. [Epub ahead of print]

97. Yoon A, Kim TJ, Lee WS, Kim BG, Bae DS. Single-port access laparoscopic staging operation for a borderline ovarian tumor. J Gynecol Oncol. 2011 Jun 30;22(2):127-30.

98. Song T, Choi CH, Lee YY, Kim TJ, Lee JW, Kim BG, Bae DS. Which is worse: uterine papillary serous carcinomas or carcinosarcomas? J Gynecol Oncol. 2011 Jun 30;22(2):83-8.

99. Song T, Kim TJ, Lee YY, Choi CH, Lee JW, Kim BG, Bae DS. What is the learning curve for single-port access laparoscopic-assisted vaginal hysterectomy? Eur J Obstet Gynecol Reprod Biol. 2011 Sep;158(1):93-6. Epub 2011 Aug 5.

100. Yoon G, Kim TJ, Sung CO, Choi CH, Lee JW, Lee JH, Bae DS, Kim BG. Benign metastasizing leiomyoma with multiple lymph node metastasis: a case report. Cancer Res Treat. 2011 Jun;43(2):131-3. Epub 2011 Jun 30.

101. Kim YS, Lim HK, Kim JH, Rhim H, Park BK, Keserci B, Köhler MO, Bae DS, Kim BG, Lee JW, Kim TJ, Sokka S, Lee JH. Dynamic contrast-enhanced magnetic resonance imaging predicts immediate therapeutic response of magnetic resonance-guided high-intensity focused ultrasound ablation of symptomatic uterine fibroids. Invest Radiol. 2011 Oct;46(10):639-47.

102. Lee YY, Kim TJ, Kim MJ, Kim HJ, Song T, Kim MK, Choi CH, Lee JW, Bae DS, Kim BG.Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis. Gynecol Oncol. 2011 Sep;122(3):541-7. Epub 2011 Jun 2.

103. Song T, Kim TJ, Kang H, Lee YY, Choi CH, Lee JW, Kim BG, Bae DS. A review of the technique and complications from 2,012 cases of laparoscopically assisted vaginal hysterectomy at a single institution. Aust N Z J Obstet Gynaecol. 2011 Jun;51(3):239-43. doi: 10.1111/j.1479-828X.2011.01296.x.

104. Kim MK, Kim TJ, Sung CO, Choi CH, Lee JW, Bae DS, Kim BG.Clinical significance of HIF-2α immunostaining area in radioresistant cervical cancer. J Gynecol Oncol. 2011 Mar 31;22(1):44-8.

105. Lee YY, Choi CH, Do IG, Song SY, Lee W, Park HS, Song TJ, Kim MK, Kim TJ, Lee JW, Bae DS, Kim BG.Prognostic value of the copper transporters, CTR1 and CTR2, in patients with ovarian carcinoma receiving platinum-based chemotherapy.Gynecol Oncol. 2011 Aug;122(2):361-5. Epub 2011 May 13.

106. Ledermann JA, Marth C, Carey MS, Birrer M, Bowtell DD, Kaye S, McNeish I, Oza A, Scambia G, Rustin G, Stehman FB, Gershenson D, Thomas G, Berns E, Casado A, Ottevanger N, Hilpert F, Kim BG, Okamoto A, Bacon M, Kitchener H, Stuart GC; Gynecologic Cancer InterGroup.Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer. Int J Gynecol Cancer. 2011 May;21(4):763-70. Review.

107. Song T, Choi CH, Park HS, Kim MK, Lee YY, Kim TJ, Lee JW, Bae DS, Kim BG. Fertility-sparing surgery for borderline ovarian tumors: oncologic safety and reproductive outcomes.Int J Gynecol Cancer. 2011 May;21(4):640-6.

108. Song T, Hun Choi C, Lee YY, Kim TJ, Lee JW, Bae DS, Kim BG.Oncologic and reproductive outcomes of cystectomy compared with oophorectomy as a treatment for borderline ovarian tumours.Hum Reprod. 2011 Aug;26(8):2008-14. Epub 2011 Apr 21.

109. Song T, Choi CH, Kim HJ, Kim MK, Kim TJ, Lee JW, Bae DS, Kim BG. Accuracy of frozen section diagnosis of borderline ovarian tumors. Gynecol Oncol. 2011 Jul;122(1):127-31. Epub 2011 Apr 13.

110. Song T, Lee JW, Kim HJ, Kim MK, Choi CH, Kim TJ, Bae DS, Kim BG. Prognostic significance of DNA ploidy in stage I endometrial cancer. Gynecol Oncol. 2011 Jul;122(1):79-82. Epub 2011 Apr 13.

111. Kang S, Kim TJ, Seo SS, Kim BG, Bae DS, Park SY.Role of Extended Chemotherapy in Advanced Ovarian Cancer Patients with High Posttreatment Serum CA-125 Levels.Gynecol Obstet Invest. 2011;72(1):50-4. Epub 2011 Mar 3.

112. Kim MK, Sung CO, Do IG, Jeon HK, Song TJ, Park HS, Lee YY, Kim BG, Lee JW, Bae DS.Overexpression of Galectin-3 and its clinical significance in ovarian carcinoma. Int J Clin Oncol. 2011 Aug;16(4):352-8. Epub 2011 Feb 16.

113. Song T, Choi CH, Kim HJ, Lee W, Lee YY, Kim TJ, Lee JW, Bae DS, Kim BG.Oncologic and reproductive outcomes in patients with advanced-stage borderline ovarian tumors. Eur J Obstet Gynecol Reprod Biol. 2011 Jun;156(2):204-8. Epub 2011 Feb 8.

114. Park B, Park S, Kim TJ, Ma SH, Kim BG, Kim YM, Kim JW, Kang S, Kim J, Kim TJ, Yoo KY, Park SK. Epidemiological characteristics of ovarian cancer in Korea. J Gynecol Oncol. 2010 Dec 30;21(4):241-7. Epub 2010 Dec 31.

115. Shin MY, Seo ES, Choi SJ, Oh SY, Kim BG, Bae DS, Kim JH, Roh CR.The role of prophylactic cerclage in preventing preterm delivery after electrosurgical conization. J Gynecol Oncol. 2010 Dec 30;21(4):230-6. Epub 2010 Dec 31.

116. Choi SY, Kim TH, Park HS, Sung CO, Lee JW, Song SY, Kim BG, Bae DS. Myxoid malignant fibrous histiocytoma of the ovary: a case report. Int J Clin Oncol. 2011 Oct;16(5):601-4. Epub 2011 Jan 6.

117. Park K, Chung YJ, So H, Kim K, Park J, Oh M, Jo M, Choi K, Lee EJ, Choi YL, Song SY, Bae DS, Kim BG, Lee JH. AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration. Exp Mol Med. 2011 Feb 28;43(2):91-100.

118. Kim WY, Lee JW, Park YA, Choi JJ, Sung CO, Song SY, Choi CH, Kim TJ, Huh SJ, Kim BG, Bae DS. RAR-beta expression is associated with early volumetric changes to radiation therapy in cervical cancer. Gynecol Obstet Invest. 2011;71(1):11-8. Epub 2010 Dec 15.

119. Lee YY, Choi CH, Kim TJ, Lee JW, Kim BG, Lee JH, Bae DS.A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB-IIA. Gynecol Oncol. 2011 Mar;120(3):439-43. Epub 2010 Dec 8.

120. Kim CJ, Lee JW, Choi JJ, Choi HY, Park YA, Jeon HK, Sung CO, Song SY, Lee YY, Choi CH, Kim TJ, Lee JH, Kim BG, Bae DS. High claudin-7 expression is associated with a poor response to platinum-based chemotherapy in epithelial ovarian carcinoma. Eur J Cancer. 2011 Apr;47(6):918-25. Epub 2010 Dec 4.

121. Nam H, Huh SJ, Park W, Bae DS, Kim BG, Lee JH, Kim CK, Park BK.Prognostic significance of MRI-detected bladder muscle and/or serosal invasion in patients with cervical cancer treated with radiotherapy. Br J Radiol. 2010 Oct;83(994):868-73.

122. Choi CH, Lee JS, Kim SR, Kim TJ, Lee JW, Kim BG, Bae DS.Clinical significance of pmTOR expression in endometrioid endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol. 2010 Dec;153(2):207-10. Epub 2010 Aug 21.

123. Kim SH, Kang S, Kim YM, Kim BG, Seong SJ, Cha SD, Park CY, Yun YH. Prevalence and predictors of anxiety and depression among cervical cancer survivors in Korea. Int J Gynecol Cancer. 2010 Aug;20(6):1017-24.

124. Choi CH, Song SY, Kang H, Lee YY, Kim CJ, Lee JW, Kim TJ, Kim BG, Lee JH, Bae DS.Prognostic significance of p-STAT3 in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy. J Obstet Gynaecol Res. 2010 Apr;36(2):304-10.

125. Lee EJ, Kim TJ, Choi CH, Lee JW, Lee JH, Bae DS, Park HM, Kim BG. Uterine Endometrial Carcinoma: 10 Years' Experience with Long-Term Follow-Up at a Single Korean Institution Gynecol Obstet Invest. 2012 Oct 11. [Epub ahead of print]

126. Song T, Kim TJ, Cho J, Kim IR, Kang PN, Lee JW, Bae DS, Kim BG. Cosmesis and body image after single-port access surgery for gynaecologic disease. Aust N Z J Obstet Gynaecol. 2012 Oct;52(5):465-9.

127. Jeong BK, Choi DH, Huh SJ, Park W, Bae DS, Kim BG. The role of squamous cell carcinoma antigen as a prognostic and predictive factor in carcinoma of uterine cervix. Radiation Oncol J. 2011 Sep;29(3):191-8. Epub 2011 Sep 30.

128. Lee YY, Song SY, Do IG, Kim TJ, Kim BG, Lee JW, Bae DS. Dynamin 2 expression as a biomarker in grading of cervical intraepithelial neoplasia. Eur J Obstet Gynecol Reprod Biol. 2012 Oct;164(2):180-4.

129. Kim HJ, Do IG, Jeon HK, Cho YJ, Park YA, Choi JJ, Sung CO, Lee YY, Choi CH, Kim TJ, Kim BG, Lee JW, Bae DS. Galectin 1 expression is associated with tumor invasion and metastasis in stage IB to IIA cervical cancer. Hum Pathol. 2012 Aug 30. [Epub ahead of print]

130. Yoon NR, Lee JW, Kim BG, Bae DS, Sohn I, Sung CO, Song SY. Gliomatosis peritonei is associated with frequent recurrence, but does not affect overall survival in patients with ovarian immature teratoma. Virchows Arch. 2012 Sep;461(3):299-304. Epub 2012 Jul 21.

131. Park JS, Ryu JY, Jeon HK, Cho YJ, Park YA, Choi JJ, Lee JW, Kim BG, Bae DS. The effects of selenium on tumor growth in epithelial ovarian carcinoma. J Gynecol Oncol. 2012 Jul;23(3):190-6.

132. Kim MK, Kim SH, Lee YY, Choi CH, Kim TJ, Lee JW, Lee JH, Bae DS, Kim BG. Metastatic skin lesions on lower extremities in a patient with recurrent serous papillary ovarian carcinoma: a case report and literature review. Cancer Res Treat. 2012 Jun;44(2):142-5. Epub 2012 Jun 30.

133. Lee YY, Choi CH, Sung CO, Do IG, Hub SJ, Kim HJ, Kim TJ, Lee JW, Bae DS, Kim BG. Clinical significance of changes in peripheral lymphocyte count after surgery in early cervical cancer. Gynecol Oncol. 2012 Oct;127(1):107-13. Epub 2012 Jun 15.

134. Choi CH, Lee JW, Lee YY, Kim HJ, Song T, Kim MK, Kim TJ, Kim BG, Bae DS. Comparison of Laparoscopic-Assisted Radical Vaginal Hysterectomy and Laparoscopic Radical Hysterectomy in the Treatment of Cervical Cancer. Ann Surg Oncol. 2012 May 30. [Epub ahead of print]

135. Choi CH, Choi JJ, Park YA, Lee YY, Song SY, Sung CO, Song T, Kim MK, Kim TJ, Lee JW, Kim HJ, Bae DS, Kim BG. Identification of differentially expressed genes according to chemosensitivity in advanced ovarian serous adenocarcinomas: expression of GRIA2 predicts better survival. Br J Cancer. 2012 Jun 26;107(1):91-9. doi: 10.1038/bjc.2012.217. Epub 2012 May 29.

136. Kim YC, Kim BG, Lee JH. Thymosin β10 expression driven by the human TERT promoter induces ovarian cancer-specific apoptosis through ROS production. PLoS One. 2012;7(5):e35399. Epub 2012 May 18

137. Song T, Choi CH, Lee YY, Kim TJ, Lee JW, Kim BG, Bae DS. Sexual function after surgery for early-stage cervical cancer: is there a difference in it according to the extent of surgical radicality? J Sex Med. 2012 Jun;9(6):1697-704. doi: 10.1111/j.1743-6109.2012.02723.x. Epub 2012 Apr 30

138. Choi JW, Lee JW, Kim JK, Jeon HK, Choi JJ, Kim DG, Kim BG, Nam DH, Kim HJ, Yun SH, Kim S. Splicing variant of AIMP2 as an effective target against chemoresistant ovarian cancer. J Mol Cell Biol. 2012 Jun;4(3):164-73. Epub 2012 Apr 24

139. Choi CH, Park YA, Choi JJ, Song T, Song SY, Lee YY, Lee JW, Kim TJ, Kim BG, Bae DS. Angiotensin II type I receptor and miR-155 in endometrial cancers: synergistic antiproliferative effects of anti-miR-155 and losartan on endometrial cancer cells. Gynecol Oncol. 2012 Jul;126(1):124-31. Epub 2012 Apr 21.

140. Lee YY, Choi CH, Kim HJ, Kim TJ, Lee JW, Lee JH, Bae DS, Kim BG. Pretreatment neutrophil:lymphocyte ratio as a prognostic factor in cervical carcinoma. Anticancer Res. 2012 Apr;32(4):1555-61.

141. Song T, Lee YY, Choi CH, Kim TJ, Lee JW, Kim BG, Bae DS. Prognosis in patients with serous and mucinous stage I borderline ovarian tumors. Int J Gynecol Cancer. 2012 Jun;22(5):770-7. doi: 10.1097/IGC.0b013e31824b4076.

142. Kim HJ, Kim TJ, Song T, Kim MK, Lee YY, Choi CH, Lee JW, Bae DS, Kim BG. Patterns of recurrence in endometrial cancer patients at risk of lymph node metastasis or recurrence according to extent of lymphadenectomy. Int J Gynecol Cancer. 2012 May;22(4):611-6.

143. Kim HJ, Jeon HK, Cho YJ, Park YA, Choi JJ, Do IG, Song SY, Lee YY, Choi CH, Kim TJ, Bae DS, Lee JW, Kim BG. High galectin-1 expression correlates with poor prognosis and is involved in epithelial ovarian cancer proliferation and invasion. Eur J Cancer. 2012 Aug;48(12):1914-21.

144. Song T, Kim TJ, Kang H, Lee YY, Choi CH, Lee JW, Kim BG, Bae DS. Factors associated with complications and conversion to laparotomy in women undergoing laparoscopically assisted vaginal hysterectomy. Acta Obstet Gynecol Scand. 2012 May;91(5):620-4.

145. Kim TJ, Lee YY, An JJ, Choi CH, Lee JW, Kim BG, Bae DS. Does single-port access (SPA) laparoscopy mean reduced pain? A retrospective cohort analysis between SPA and conventional laparoscopy. Eur J Obstet Gynecol Reprod Biol. 2012 May;162(1):71-4. Epub 2012 Feb 14.

146. Song T, Choi CH, Cho YJ, Sung CO, Song SY, Kim TJ, Bae DS, Lee JW, Kim BG. Expression of 67-kDa laminin receptor was associated with tumor progression and poor prognosis in epithelial ovarian cancer. Gynecol Oncol. 2012 May;125(2):427-32. Epub 2012 Jan 28.

147. Kim HS, Choi CH, Lim MC, Chang SJ, Kim YB, Kim MA, Kim TJ, Park SY, Kim BG, Song YS, Bae DS, Kim JW. Safe criteria for less radical trachelectomy in patients with early-stage cervical cancer: a multicenter clinicopathologic study. Ann Surg Oncol. 2012 Jun;19(6):1973-9. Epub 2011 Dec 20.

148. Song T, Kim TJ, Kang HJ, Choi CH, Lee JW, Bae DS, Kim BG. Single-port access laparoscopic surgery using a novel laparoscopic port (Octo-Port). Taiwan J Obstet Gynecol. 2011 Dec;50(4):436-40.

149. Kim MK, Song SY, Do IG, Kim SH, Choi CH, Kim TJ, Lee JW, Bae DS, Kim BG. Synchronous gynecologic malignancy and preliminary results of Lynch syndrome. J Gynecol Oncol. 2011 Dec;22(4):233-8.

150. Kang S, Kim TJ, Seo SS, Kim BG, Bae DS, Park SY. Prediction of a high-risk group based on postoperative nadir CA-125 levels in patients with advanced epithelial ovarian cancer. J Gynecol Oncol. 2011 Dec;22(4):269-74.

151. Yoon G, Kim YS, Kim BG, Bae DS, Lee JW. Long-term recurrence-free survival in a patient with stage IVB uterine carcinosarcoma.

J Gynecol Oncol. 2011 Dec;22(4):292-4..

152. Kim YS, Bae DS, Kim BG, Lee JW, Kim TJ. A faster nonsurgical solution very large fibroid tumors yielded to a new ablation strategy. Am J Obstet Gynecol. 2011 Sep;205(3):292.e1-5..

153. Park YA, Lee JW, Choi JJ, Jeon HK, Cho Y, Choi C, Kim TJ, Lee NW, Kim BG, Bae DS. The interactions between MicroRNA-200c and BRD7 in endometrial carcinoma. Gynecol Oncol. 2012 Jan;124(1):125-33.

154. Lee YY, Choi CH, Sung CO, Do IG, Huh S, Song T, Kim MK, Kim HJ, Kim TJ, Lee JW, Kim BG, Bae DS. Prognostic value of pre-treatment circulating monocyte count in patients with cervical cancer: comparison with SCC-Ag level. Gynecol Oncol. 2012 Jan;124(1):92-7..

155. Song T, Lee JW, Choi CH, Kim TJ, Bae DS, Sung CO, Song SY, Kim BG. Ploidy and S-phase fraction are correlated with lymphovascular space invasion that is predictive of outcomes in endometrial cancer. Int J Clin Oncol. 2011 Oct 13. [Epub ahead of print.

156. Ryu JH, Choi CH, Kim TJ, Lee JW, Kim BG, Bae DS. Chemo-resistan t choriocarcinoma metastatic to colon cured by low-anterior resection. J Gynecol Oncol. 2011 Sep;22(3):203-6..

157. Yoon A, Kim TJ, Lee WS, Kim BG, Bae DS. Single-port access laparoscopic staging operation for a borderline ovarian tumor. J Gynecol Oncol. 2011 Jun 30;22(2):127-30.

158. Song T, Choi CH, Lee YY, Kim TJ, Lee JW, Kim BG, Bae DS. Which is worse: uterine papillary serous carcinomas or carcinosarcomas? J Gynecol Oncol. 2011 Jun 30;22(2):83-8.

159. Song T, Kim TJ, Lee YY, Choi CH, Lee JW, Kim BG, Bae DS. What is the learning curve for single-port access laparoscopic-assisted vaginal hysterectomy? Eur J Obstet Gynecol Reprod Biol. 2011 Sep;158(1):93-6..

160. Yoon G, Kim TJ, Sung CO, Choi CH, Lee JW, Lee JH, Bae DS, Kim BG. Benign metastasizing leiomyoma with multiple lymph node metastasis: a case report. Cancer Res Treat. 2011 Jun;43(2):131-3.

162. Kim YS, Lim HK, Kim JH, Rhim H, Park BK, Keserci B, Köhler MO, Bae DS, Kim BG, Lee JW, Kim TJ, Sokka S, Lee JH. Dynamic contrast-enhanced magnetic resonance imaging predicts immediate therapeutic response of magnetic resonance-guided high-intensity focused ultrasound ablation of symptomatic uterine fibroids. Invest Radiol. 2011 Oct;46(10):639-47.

163. Lee EJ, Kim TJ, Choi CH, Lee JW, Lee JH, Bae DS, Park HM, Kim BG Uterine endometrial carcinoma: 10 years' experience with long-term follow-up at a single Korean institution. Gynecol Obstet Invest. 2012;74(4):313-9.

164. Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Kim YS, Kim HJ, Lee JW, Kim BG, Bae DS, Huh SJ, Nam JH. Comparison of outcomes between radical hysterectomy followed by tailored adjuvant therapy versus primary chemoradiation therapy in IB2 and IIA2 cervical cancer. J Gynecol Oncol. 2012 Oct;23(4):226-34.

165. Ma SH, Kim BG, Choi JY, Kim TJ, Kim YM, Kim JW, Kang S, Kang D, Yoo KY, Park SK. Korean epithelial ovarian cancer study (Ko-EVE): protocols and interim report. Asian Pac J Cancer Prev. 2012;13(8):3731-40

166. Lee YY, Cho YJ, Choi JJ, Choi CH, Kim TJ, Kim BG, Bae DS, Kim YS, Lee JW. The effect of high-intensity focused ultrasound in combination with cisplatin using a Xenograft model of cervical cancer. Anticancer Res. 2012 Dec;32(12):5285-9

167. Choi CH, Sung CO, Kim HJ, Lee YY, Song SY, Song T, Kim J, Kim TJ, Lee JW, Bae DS, Kim BG. Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary. Hum Pathol. 2013 Jun;44(6):1017-23.

168. Jo EJ, Lee YY, Kim TJ, Choi CH, Lee JW, Bae DS, Kim BG. Management and outcome of rectal injury during gynecologic laparoscopic surgery. J Minim Invasive Gynecol. 2013 Mar;20(2):166-71.

169. Jo EJ, Kim TJ, Lee YY, Choi CH, Lee JW, Bae DS, Kim BG. Laparoendoscopic single-site surgery with hysterectomy in patients with prior cesarean section: comparison of surgical outcomes with bladder dissection techniques. J Minim Invasive Gynecol. 2013 Mar;20(2):160-5.

170. Park JY, Kim TJ, Kang HJ, Lee YY, Choi CH, Lee JW, Bae DS, Kim BG. Laparoendoscopic single site (LESS) surgery in benign gynecology: perioperative and late complications of 515 cases. Eur J Obstet Gynecol Reprod Biol. 2013 Apr;167(2):215-8.

171. Song T, Lee YY, Choi CH, Kim TJ, Lee JW, Bae DS, Kim BG. Histologic distribution of borderline ovarian tumors worldwide: a systematic review. J Gynecol Oncol. 2013 Jan;24(1):44-51.

172. Noh JM, Park W, Huh SJ, Cho EY, Choi YL, Bae DS, Kim BG. Prognostic implications of tumor volume response and COX-2 expression change during radiotherapy in cervical cancer patients. Radiat Oncol J. 2012 Dec;30(4):218-25.

173. Song T, Cho J, Kim TJ, Kim IR, Hahm TS, Kim BG, Bae DS. Cosmetic Outcomes of Laparoendoscopic Single-Site Hysterectomy Compared With Multi-Port Surgery: Randomized Controlled Trial. J Minim Invasive Gynecol. 2013 Mar 26. doi:pii: S1553-4650(13)00039-3. 10.1016/j.jmig.2013.01.010. [Epub ahead of print]

174. Kim HJ, Jeon HK, Lee JK, Sung CO, Do IG, Choi CH, Kim TJ, Kim BG, Bae DS, Lee JW. Clinical significance of galectin-7 in epithelial ovarian cancer. Anticancer Res. 2013 Apr;33(4):1555-61

175. Herzog TJ, Scambia G, Kim BG, Lhommé C, Markowska J, Ray-Coquard I, Sehouli J, Colombo N, Shan M, Petrenciuc O, Oza A. A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. Gynecol Oncol. 2013 Jul;130(1):25-30

176. Jeong BK, Huh SJ, Choi DH, Park W, Bae DS, Kim BG. Prognostic value of different patterns of squamous cell carcinoma antigen level for the recurrent cervical cancer. Cancer Res Treat. 2013 Mar;45(1):48-54.

177. Kim HJ, Kim TJ, Lee YY, Choi CH, Lee JW, Bae DS, Kim BG. A comparison of uterine papillary serous, clear cell carcinomas, and grade 3 endometrioid corpus cancers using 2009 FIGO staging system. J Gynecol Oncol. 2013 Apr;24(2):120-7. doi: 10.3802/jgo.2013.24.2.120. Epub 2013 Apr 5

178. Lee JK, Hong JH, Kang S, Kim DY, Kim BG, Kim SH, Kim YM, Kim JW, Kim JH, Kim TJ, Kim HJ, Kim HS, Ryu HS, Song JY, Ahn HS, Yoo CW, Yoon HK, Lee KH, Lee A, Lee Y, Lee IH, Lee JW, Lee TS, Lim MC, Chang SJ, Chung HH, Ju W, Joo HJ, Hur SY, Hong SR, Nam JH. Practice guidelines for the early detection of cervical cancer in Korea: Korean Society of Gynecologic Oncology and the Korean Society for Cytopathology 2012 edition. J Gynecol Oncol. 2013 Apr;24(2):186-203. doi: 10.3802/jgo.2013.24.2.186. Epub 2013 Apr 5

179. Kim B, Huh SJ, Kim BG.Port site metastasis after robotic-assisted laparoscopic hysterectomy for uterine cervical cancer: A case report and literature review. Taiwan J Obstet Gynecol. 2013 Dec;52(4):558-63. doi: 10.1016/j.tjog.2013.10.018.

180. Choi CH, Kim TH, Kim SH, Choi JK, Park JY, Yoon A, Lee YY, Kim TJ, Lee JW, Kim BG, Bae DS. Surgical outcomes of a new approach of laparoscopic myomectomy: single port and modified suture technique. J Minim Invasive Gynecol. 2013 Dec 30. pii: S1553-4650(13)01555-0. doi: 10.1016/j.jmig.2013.12.096. [Epub ahead of print

181. Ryu SY, Kim MH, Nam BH, Lee TS, Song ES, Park CY, Kim JW, Kim YB, Ryu HS, Park SY, Kim KT, Cho CH, Lee C, Kim SM, Kim BG, Bae DS, Kim YT, Nam JH. Intermediate-risk grouping of cervical cancer patients treated with radical hysterectomy: a Korean Gynecologic Oncology Group study. Br J Cancer. 2013 Dec 19. doi: 10.1038/bjc.2013.716. [Epub ahead of print]

182. Yoon A, Choi CH, Kim TH, Choi JK, Park JY, Lee YY, Kim TJ, Lee JW, Bae DS, Kim BG. Bone metastasis in primary endometrial carcinoma: features, outcomes, and predictors. Int J Gynecol Cancer. 2014 Jan;24(1):107-12.

183. Choi CH, Kim MK, Park JY, Yoon A, Kim HJ, Lee YY, Kim TJ, Lee JW, Kim BG, Bae DS. Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin. Support Care Cancer. 2013 Dec 12. [Epub ahead of print]

184. Park YA, Lee JW, Kim HS, Lee YY, Kim TJ, Choi CH, Choi JJ, Jeon HK, Cho YJ, Ryu JY, Kim BG, Bae DS. Tumor Suppressive Effects of Bromodomain-Containing Protein 7 (BRD7) in Epithelial Ovarian Carcinoma. Clin Cancer Res. 2014 Jan 16. [Epub ahead of print]

185. Song T, Choi CH, Lee YY, Kim TJ, Lee JW, Sung CO, Song SY, Bae DS, Kim BG. Endocervical-like versus intestinal-type mucinous borderline ovarian tumors: a large retrospective series focusing on the clinicopathologic characteristics. Gynecol Obstet Invest. 2013;76(4):241-7. doi: 10.1159/000356072. Epub 2013 Nov 1.

186. Yoon A, Park JY, Park JY, Lee YY, Kim TJ, Choi CH, Bae DS, Kim BG, Lee JW, Nam JH. Prognostic factors and outcomes in endometrial stromal sarcoma with the 2009 FIGO staging system: A multicenter review of 114 cases.Gynecol Oncol. 2013 Oct 31. pii: S0090-8258(13)01278-X. doi: 10.1016/j.ygyno.2013.10.029. [Epub ahead of print

187. Kim BG.Squamous cell carcinoma antigen in cervical cancer and beyond. J Gynecol Oncol. 2013 Oct;24(4):291-2. doi: 10.3802/jgo.2013.24.4.291. Epub 2013 Oct 2

188. Lee YY, Kim TJ, Kim JY, Choi CH, Do IG, Song SY, Sohn I, Jung SH, Bae DS, Lee JW, Kim BG. Genetic profiling to predict recurrence of early cervical cancer. Gynecol Oncol. 2013 Dec;131(3):650-4. doi: 10.1016/j.ygyno.2013.10.003. Epub 2013 Oct 18

189. Lee HJ, Han S, Kim YS, Nam JH, Kim HJ, Kim JW, Park W, Kim BG, Kim JH, Cha SD, Kim J, Lee KH, Yoon MS, Kim SM, Kim JY, Yoon WS, Lee NW, Choi JH, Park SY, Kim JY. Individualized prediction of overall survival after postoperative radiation therapy in patients with early-stage cervical cancer: a Korean Radiation Oncology Group study (KROG 13-03). Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):659-64. doi: 10.1016/j.ijrobp.2013.07.020

190. Lee YY, Park W, Huh SJ, Yoon A, Park JY, Choi CH, Kim TJ, Lee JW, Kim BG, Bae DS. Platinum-based combination chemotherapy vs. weekly cisplatin during adjuvant CCRT in early cervical cancer with pelvic LN metastasis. Anticancer Res. 2013 Oct;33(10):4675-81

191. Jung DC, Kang S, Kim SC, Kim JW, Nam JH, Ryu SY, Seong SJ, Kim BG. Use of complex surgical procedures, patterns of tumor spread, and CA-125 predicts a risk of incomplete cytoreduction: a Korean Gynecologic Oncology Group study (KGOG-3022). Gynecol Oncol. 2013 Nov;131(2):336-40. doi: 10.1016/j.ygyno.2013.07.110. Epub 2013 Aug 13

192. Song T, Kim MK, Lee YY, Choi CH, Kim TJ, Lee JW, Kim BG, Bae DS. Phase II study of ifosfamide and cisplatin for the treatment of recurrent ovarian cancer. Cancer Chemother Pharmacol. 2013 Sep;72(3):653-60. doi: 10.1007/s00280-013-2241-7. Epub 2013 Aug 3

193. Lee JW, Park YA, Cho YJ, Kang KH, Choi JJ, Lee YY, Kim TJ, Choi CH, Kim BG, Bae DS. The effect of surgical wound on ovarian carcinoma growth in an animal model. Anticancer Res. 2013 Aug;33(8):3177-84

194. Lee HY, Yang BM, Hong JM, Lee TJ, Kim BG, Kim JW, Kim YT, Kim YM, Kang S. Cost-utility analysis for platinum-sensitive recurrent ovarian cancer therapy in South Korea: results of the polyethylene glycolated liposomal doxorubicin/carboplatin sequencing model. Clinicoecon Outcomes Res. 2013 Jul 3;5:297-307. doi: 10.2147/CEOR.S42170. Print 2013

195. Yoon A, Choi CH, Kim HJ, Park JY, Lee YY, Kim TJ, Lee JW, Bae DS, Kim BG. Contributing factors for bone metastasis in uterine cervical cancer. Int J Gynecol Cancer. 2013 Sep;23(7):1311-7. doi: 10.1097/IGC.0b013e31829da127

196. Sung CO, Choi CH, Ko YH, Ju H, Choi YL, Kim N, Kang SY, Ha SY, Choi K, Bae DS, Lee JW, Kim TJ, Song SY, Kim BG. Integrative analysis of copy number alteration and gene expression profiling in ovarian clear cell adenocarcinoma. Cancer Genet. 2013 May;206(5):145-53. doi: 10.1016/j.cancergen.2013.04.002. Epub 2013 May 29

197. Choi CH1, Song T, Kim TH, Choi JK, Park JY, Yoon A, Lee YY, Kim TJ, Bae DS, Lee JW, Kim BG. Meta-analysis of the effects of beta blocker on survival time in cancer patients. J Cancer Res Clin Oncol. 2014 Mar 27. [Epub ahead of print]

198. Park JY, Lee JW, Park BK, Lee YY, Choi CH, Kim TJ, Bae DS, Kim BG, Park JJ, Park SY, Kim CK. Postoperative outcomes of MR-invisible stage IB1 cervical cancer. Am J Obstet Gynecol. 2014 Mar 4. pii: S0002-9378(14)00174-4. doi: 10.1016/j.ajog.2014.02.032. [Epub ahead of print]

199. Kim TJ, Song T, Choi CH, Lee JW, Bae DS, Kim BG. Comparison of laparoendoscopic single-site hysterectomies: laparoscopic hysterectomy with some vaginal component versus laparoscopically assisted vaginal hysterectomy. J Laparoendosc Adv Surg Tech A. 2014 Apr;24(4):254-9.

200. Yoon H, Choi YL, Song JY, Do I, Kang SY, Ko YH, Song S, Kim BG. Targeted inhibition of FAK, PYK2 and BCL-XL synergistically enhances apoptosis in ovarian clear cell carcinoma cell lines. PLoS One. 2014 Feb 11;9(2):e88587. doi: 10.1371/journal.pone.0088587. eCollection 2014

201. Yoon A, Kim TJ, Lee YY, Choi CH, Lee JW, Bae DS, Kim BG. Laparoendoscopic single-site (LESS) myomectomy: characteristics of the appropriate myoma. Eur J Obstet Gynecol Reprod Biol. 2014 Apr;175:58-61.

202. Kim B, Huh SJ, Kim BG. Port site metastasis after robotic-assisted laparoscopic hysterectomy for uterine cervical cancer: a case report and literature review. Taiwan J Obstet Gynecol. 2013 Dec;52(4):558-63.

203. Choi CH, Kim TH, Kim SH, Choi JK, Park JY, Yoon A, Lee YY, Kim TJ, Lee JW, Kim BG, Bae DS. Surgical outcomes of a new approach of laparoscopic myomectomy: single port and modified suture technique. J Minim Invasive Gynecol. 2013 Dec 30. pii: S1553-4650(13)01555-0. doi: 10.1016/j.jmig.2013.12.096. [Epub ahead of print]

204. Kim YS, Kim BG, Rhim H, Bae DS, Lee JW, Kim TJ, Choi CH, Lee YY, Lim HK. Uterine Fibroids: Semiquantitative Perfusion MR Imaging Parameters Associated with the Intraprocedural and Immediate Postprocedural Treatment Efficiencies of MR Imaging-guided High-Intensity Focused Ultrasound Ablation. Radiology. 2014 Jul 1:132719. [Epub ahead of print]

205. Song T, Lee YY, Choi CH, Kim TJ, Lee JW, Bae DS, Kim BG. Risk Factors for Progression to Invasive Carcinoma in Patients With Borderline Ovarian Tumors. Int J Gynecol Cancer. 2014 Jul 30. [Epub ahead of print]

206. Cho H, Nam BH, Kim SM, Cho CH, Kim BG, Ryu HS, Kang SB, Kim JH. A Phase 2 Trial of Radiation Therapy With Concurrent Paclitaxel Chemotherapy After Surgery in Patients With High-Risk Endometrial Cancer: A Korean Gynecologic Oncologic Group Study. Int J Radiat Oncol Biol Phys. 2014 Jul 8. pii: S0360-3016(14)00624-5. doi: 10.1016/j.ijrobp.2014.05.024. [Epub ahead of print]

207. Park YA, Choi CH, Do IG, Song SY, Lee JK, Cho YJ, Choi JJ, Jeon HK, Ryu JY, Lee YY, Kim TJ, Bae DS, Lee JW, Kim BG. Dual targeting of angiotensin receptors (AGTR1 and AGTR2) in epithelial ovarian carcinoma. Gynecol Oncol. 2014 Jul 9. pii: S0090-8258(14)01072-5. doi: 10.1016/j.ygyno.2014.06.031. [Epub ahead of print]

208. Kim HJ, Sung JH, Lee E, Ahn S, Song SY, Choi CH, Kim TJ, Kim BG, Bae DS, Lee JW. Prognostic Factors Influencing Decisions About Surgical Treatment of Villoglandular Adenocarcinoma of the Uterine Cervix. Int J Gynecol Cancer. 2014 Jul 1. [Epub ahead of print]

209. Yoon A1, Yoo HN1, Lee YY1, Lee JW1, Kim BG1, Bae DS1, Kim TJ2. Robotic Single-Port hysterectomy, adnexectomy and lymphadenectomy in Endometrial Cancer. J Minim Invasive Gynecol. 2014 Dec 10. pii: S1553-4650(14)01594-5. doi: 10.1016/j.jmig.2014.12.003. [Epub ahead of print]

210. Song T, Lee YY, Choi CH, Kim TJ, Lee JW, Bae DS, Kim BG. Borderline ovarian tumor in women aged ≥65 years: impact on recurrence and survival. Eur J Obstet Gynecol Reprod Biol. 2015 Jan;184:38-42. doi: 10.1016/j.ejogrb.2014.10.001. Epub 2014 Oct 14.

211. Lee JW, Ryu JY, Yoon G, Jeon HK, Cho YJ, Choi JJ, Song SY, Do IG, Lee YY, Kim TJ, Choi CH, Kim BG, Bae DS. Sphingosine kinase 1 as a potential therapeutic target in epithelial ovarian cancer. Int J Cancer. 2014 Nov 27. doi: 10.1002/ijc.29362. [Epub ahead of print]

212. Kim HJ1, Choi CH2, Lee YY2, Kim TJ2, Lee JW2, Bae DS2, Kim BG3. Surgical outcome prediction in patients with advanced ovarian cancer using computed tomography scans and intraoperative findings. Taiwan J Obstet Gynecol. 2014 Sep;53(3):343-7. doi: 10.1016/j.tjog.2013.10.041

213. du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P. Incorporation of pazopanib in maintenance therapy of ovari an cancer. J Clin Oncol. 2014 Oct 20;32(30):3374-82. doi: 10.1200/JCO.2014.55.7348. Epub 2014 Sep 15

214. Kim TH, Choi CH, Choi JK, Yoon A, Lee YY, Kim TJ, Lee JW, Bae DS, Kim BG. Robotic versus laparoscopic radical hysterectomy in cervical cancer patients: a matched-case comparative study. Int J Gynecol Cancer. 2014 Oct;24(8):1466-73. doi: 10.1097/IGC.0000000000000232

215. Okamoto A, Sehouli J, Yanaihara N, Hirata Y, Braicu I, Kim BG, Takakura S, Saito M, Yanagida S, Takenaka M, Yamaguchi N, Morikawa A, Tanabe H, Yamada K, Yoshihara K, Enomoto T, Itamochi H, Kigawa J, Matsumura N, Konishi I, Aida S, Aoki Y, Ishii N, Ochiai K, Akiyama T, Urashima M. Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma. PLoS One. 2015 Feb 6;10(2):e0116977.

216. Kim YS, Lee JW, Choi CH, Kim BG, Bae DS, Rhim H, Lim HK. Uterine Fibroids: Correlation of T2 Signal Intensity with Semiquantitative Perfusion MR Parameters in Patients Screened for MR-guided High-Intensity Focused Ultrasound Ablation. Radiology. 2015 Aug 27:150608. [Epub ahead of print

217. Kim HS, Yoon G, Ryu JY, Cho YJ, Choi JJ, Lee YY, Kim TJ, Choi CH, Song SY, Kim BG, Bae DS, Lee JW. Sphingosine kinase 1 is a reliable prognostic factor and a novel therapeutic target for uterine cervical cancer. Oncotarget. 2015 Jul 28. [Epub ahead of print

218. Kim TJ, Yoon G, Lee YY, Choi CH, Lee JW, Bae DS, Kim BG. Robotic high para-aortic lymph node dissection with high port placement using same port for pelvic surgery in gynecologic cancer patients. J Gynecol Oncol. 2015 Jul;26(3):222-6

219. Paik ES, Yoon A, Lee YY, Kim TJ, Lee JW, Bae DS, Kim BG. Pulmonary metastasectomy in uterine malignancy: outcomes and prognostic factors. J Gynecol Oncol. 2015 Jul 17. [Epub ahead of print

220. Kim HS, Yoon G, Jang HI, Song SY, Kim BG. Primary ovarian carcinoid tumor showing unusual histology and nuclear accumulation of β-catenin. Int J Clin Exp Pathol. 2015 May 1;8(5):5749-52.

221. Yoon G, Kim HS, Lee YY, Kim TJ, Choi CH, Song SY, Kim BG, Bae DS, Lee JW. Mesothelial cell inclusions in pelvic and para-aortic lymph nodes: a clinicopathologic analysis Int J Clin Exp Pathol. 2015 May 1;8(5):5318-26.

222. . Yoon G, Kim HS, Lee YY, Kim TJ, Choi CH, Song SY, Kim BG, Bae DS, Lee JW. Analysis of clinical outcomes of patients with adenoid cystic carcinoma of Bartholin glands. Int J Clin Exp Pathol. 2015 May 1;8(5):5688-94.

223. Yoon G, Kim HS, Lee YY, Kim TJ, Choi CH, Kim BG, Bae DS, Hwang JH, Lee JW. Clinical outcomes of primary surgical treatment for acquired vulvar lymphangioma circumscriptum. Arch Gynecol Obstet. 2015 Jul 9. [Epub ahead of print.

224. Song T, Park JY, Kim TJ, Lee YY, Choi CH, Lee JW, Bae DS, Kim BG. A prospective comparative study of cosmetic satisfaction for three different surgical approaches. Eur J Obstet Gynecol Reprod Biol. 2015 Jul;190:48-51.

225. Oh DY, Kim S, Choi YL, Cho YJ, Oh E, Choi JJ, Jung K, Song JY, Ahn SE, Kim BG, Bae DS, Park WY, Lee JW, Song S. HER2 as a novel therapeutic target for cervical cancer. Oncotarget. 2015 Sep 21. [Epub ahead of print].

226. Lee YY, Jeon HK, Hong JE, Cho YJ, Ryu JY, Choi JJ, Lee SH, Yoon G, Kim WY, Do IG, Kim MK, Kim TJ, Choi CH, Lee JW, Bae DS, Kim BG. Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma. Oncotarget. 2015 Sep 19. [Epub ahead of print].

227. Kim JW, Mahner S, Wu LY, Shoji T, Kim BG, Zhu JQ, Takano T, Park SY, Kong BH, Wu Q, Wang KL, Ngan HY, Liu JH, Wei LH, Mitrica I, Zhang P, Crescenzo R, Wang Q, Cox CJ, Harter P, du Bois A. Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study. Int J Gynecol Cancer. 2015 Nov 19. [Epub ahead of print]

228. Lee JY, Kim K, Lee TS, Kang S, Seong SJ, Kim JW, Kim BG. Controversies in the management of endometrial cancer: a survey of the Korean Gynecologic Oncology Group. J Gynecol Oncol. 2015 Oct;26(4):277-83. doi: 10.3802/jgo.2015.26.4.277. Epub 2015 Sep 23.

229. Song T, Kim MK, Lee YY, Choi CH, Kim TJ, Lee JW, Bae DS, Kim BG. Women with double primary cancers of the colorectum and endometrium: do they have Lynch syndrome? Eur J Obstet Gynecol Reprod Biol. 2016 Apr;199:208-12. doi: 10.1016/j.ejogrb.2015.07.018. Epub 2015 Aug 20

230. Paik ES, Lee YY, Shim M, Choi HJ, Kim TJ, Choi CH, Lee JW, Kim BG, Bae DS. Timing and patterns of recurrence in epithelial ovarian cancer patients with no gross residual disease after primary debulking surgery. Aust N Z J Obstet Gynaecol. 2016 Sep 9. doi: 10.1111/ajo.12529. [Epub ahead of print]

231. Paik ES, Shim M, Choi HJ, Lee YY, Kim TJ, Lee JW, Kim BG, Bae DS, Choi CH. Impact of lymphadenectomy on survival after recurrence in patients with advanced ovarian cancer without suspected lymph node metastasis. Gynecol Oncol. 2016 Aug 23. pii: S0090-8258(16)31347-6. doi: 10.1016/j.ygyno.2016.08.321. [Epub ahead of print]

232. Sugiyama T, Okamoto A, Enomoto T, Hamano T, Aotani E, Terao Y, Suzuki N, Mikami M, Yaegashi N, Kato K, Yoshikawa H, Yokoyama Y, Tanabe H, Nishino K, Nomura H, Kim JW, Kim BG, Pignata S, Alexandre J, Green J, Isonishi S, Terauchi F, Fujiwara K, Aoki D. Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial. J Clin Oncol. 2016 Aug 20;34(24):2881-7. doi: 10.1200/JCO.2016.66.9010. Epub 2016 Jul 11.

233. Paik ES, Kim TJ, Lee YY, Choi CH, Lee JW, Kim BG, Bae DS. Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer. J Gynecol Oncol. 2016 Sep;27(5):e46. doi: 10.3802/jgo.2016.27.e46. Epub 2016 May 9

234. Yoon A, Park JJ, Park BK, Lee YY, Paik ES, Choi CH, Kim TJ, Kim CK, Lee JW, Bae DS, Kim BG. Long-term Outcomes of MRI Stage IIB Cervical Cancer. Int J Gynecol Cancer. 2016 Sep;26(7):1252-7. doi: 10.1097/IGC.0000000000000762.

235. Kim TH, Kim CJ, Kim TJ, Lee YY, Choi CH, Lee JW, Bae DS, Kim BG. Retroperitoneal Approach in Single-Port Laparoscopic Hysterectomy. JSLS. 2016 Apr-Jun;20(2). pii: e2016.00001. doi: 10.4293/JSLS.2016.00001

236. Choi CH, Chung JY, Kim JH, Kim BG, Hewitt SM. Expression of fibroblast growth factor receptor family members is associated with prognosis in early stage cervical cancer patients. J Transl Med. 2016 May 6;14(1):124. doi: 10.1186/s12967-016-0874-0.

237. Choi HJ, Lee S, Park BK, Kim TJ, Kim CK, Park JJ, Choi CH, Lee YY, Lee JW, Bae DS, Kim BG. Long-term outcomes of magnetic resonance imaging-invisible endometrial cancer. J Gynecol Oncol. 2016 Jul;27(4):e38. doi: 10.3802/jgo.2016.27.e38. Epub 2016 Apr 18.

238. Paik ES, Lee YY, Kim TJ, Choi CH, Lee JW, Kim BG, Bae DS. Feasibility of laparoscopic cytoreduction in patients with localized recurrent epithelial ovarian cancer. J Gynecol Oncol. 2016 May;27(3):e24. doi: 10.3802/jgo.2016.27.e24.

239. Kim TH, Kim HS, Kim TJ, Chang SJ, Kim DY, Ryu SY, Kim BG, Kim YT, Bae DS, Ryu HS, Nam JH. Survival impact based on the thoroughness of pelvic lymphadenectomy in intermediate- or high-risk groups of endometrioid-type endometrial cancer: A multi-center retrospective cohort analysis. Gynecol Oncol. 2016 Jun;141(3):440-6. doi: 10.1016/j.ygyno.2016.03.031. Epub 2016 Apr 8.

240. Han HD, Cho YJ, Cho SK, Byeon Y, Jeon HN, Kim HS, Kim BG, Bae DS, Lopez-Berestein G, Sood AK, Shin BC, Park YM, Lee JW. Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma. Mol Cancer Ther. 2016 Apr;15(4):618-27. doi: 10.1158/1535-7163.MCT-15-0733-T. Epub 2016 Feb 9

241. Park JY, Heo EJ, Lee JW, Lee YY, Kim TJ, Kim BG, Bae DS. Outcomes of laparoscopic fertility-sparing surgery in clinicall y early-stage epithelial ovarian cancer. J Gynecol Oncol. 2016 Mar;27(2):e20. doi: 10.3802/jgo.2016.27.e20.

242. Park B, Park S, Shin HR, Shin A, Yeo Y, Choi JY, Jung KW, Kim BG, Kim YM, Noh DY, Ahn SH, Kim JW, Kang S, Kim JH, Kim TJ, Kang D, Yoo KY, Park SK. Population attributable risks of modifiable reproductive factors for breast and ovarian cancers in Korea. BMC Cancer. 2016 Jan 6;16:5. doi: 10.1186/s12885-015-2040-0.

243. Robert L Coleman, Mark F Brady, Thomas J Herzog, Paul Sabbatini, Deborah K Armstrong, Joan L Walker, Byoung-Gie Kim, Keiichi Fujiwara,Krishnansu S Tewari, David M O’Malley, Susan A Davidson, Stephen C Rubin, Paul DiSilvestro, Karen Basen-Engquist, Helen Huang, John K Chan,Nick M Spirtos, Raheela Ashfaq, Robert S Mannel. Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised,phase 3 trial. Lancet Oncol 2017 Published OnlineApril 21, 2017 http://dx.doi.org/10.1016/S1470-2045(17)30279-6

244. Sung HK, Ma SH, Choi JY, Hwang Y, Ahn C, Kim BG, Kim YM, Kim JW, Kang S, Kim J, Kim TJ, Yoo KY, Kang D, Park S. The Effect of Breastfeeding Duration and Parity on the Risk of Epithelial Ovarian Cancer: A Systematic Review and Meta-analysis. Prev Med Public Health. 2016 Nov;49(6):349-366. Epub 2016 Sep 8. Review

245. Yang K, Park W, Huh SJ, Bae DS, Kim BG, Lee JW. Clinical outcomes in patients treated with radiotherapy after surgery for cervical cancer. Radiat Oncol J. 2017 Mar;35(1):39-47. doi: 10.3857/roj.2016.01893. Epub 2016 Dec 12

246. Kim HJ, Yoon A, Ryu JY, Cho YJ, Choi JJ, Song SY, Bang H, Lee JS, Cho WC, Choi CH, Lee JW, Kim BG, Bae DS. c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma. Sci Rep. 2016 Dec 5;6:38502. doi: 10.1038/srep38502.

247. Song T, Seong SJ, Kim BG. Regeneration Process After Cervical Conization for Cervical Intraepithelial Neoplasia. Obstet Gynecol. 2016 Dec;128(6):1258-1264

248. Nam SH, Choi HJ, Kang WD, Kim SM, Lim MC, Park SY, Kim JS, Kim BG, Bae DS, Lee JW, Kim TJ, Song T. Development and Validation of the Korean Version of Hand-Foot Skin Reaction and Quality of Life Questionnaire (HF-QoL-K). Korean Med Sci. 2016 Dec;31(12):1969-1975. doi: 10.3346/jkms.2016.31.12.1969

249. Choi CH, Ryu JY, Cho YJ, Jeon HK, Choi JJ, Ylaya K, Lee YY, Kim TJ, Chung JY, Hewitt SM, Kim BG, Bae DS, Lee JW. The anti-cancer effects of itraconazole in epithelial ovarian cancer. Sci Rep. 2017 Jul 26;7(1):6552. doi: 10.1038/s41598-017-06510-7.

250. Song T, Lee DH, Jung YW, Yun BS, Seong SJ, Choi CH, Lee JW, Bae DS, Kim BG. Elevated Preoperative CA125 or CA19-9 in Borderline Ovarian Tumors: Could It Be Suggestive of Advanced Stage or a Poor Prognosis? Gynecol Obstet Invest. 2018;83(1):45-51. doi: 10.1159/000475817. Epub 2017 Jun 2

251. Paik ES, Choi HJ, Kim TJ, Lee JW, Kim BG, Bae DS, Choi CH. Molecular Signature for Lymphatic Invasion Associated with Survival of Epithelial Ovarian Cancer. Cancer Res Treat. 2018 Apr;50(2):461-473. doi: 10.4143/crt.2017.104. Epub 2017 May 22

252. Jang JYA, Yanaihara N, Pujade-Lauraine E, Mikami Y, Oda K, Bookman M, Ledermann J, Shimada M, Kiyokawa T, Kim BG, Matsumura N, Kaku T, Kuroda T, Nagayoshi Y, Kawabata A, Iida Y, Kim JW, Quinn M, Okamoto A. Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference. J Gynecol Oncol. 2017 Jul;28(4):e54. doi: 10.3802/jgo.2017.28.e54. Review.

253. Song T, Kim MK, Jung YW, Yun BS, Seong SJ, Choi CH, Kim TJ, Lee JW, Bae DS, Kim BG. Minimally invasive compared with open surgery in patients with borderline ovarian tumors. Gynecol Oncol. 2017 Jun;145(3):508-512. doi: 10.1016/j.ygyno.2017.03.019. Epub 2017 Apr 2

254. Lee SW, Kim YM, Cho CH, Kim YT, Kim SM, Hur SY, Kim JH, Kim BG, Kim SC, Ryu HS, Kang SB. An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: A Korean Gynecologic Oncology Group Study (KGOG-3021). Cancer Res Treat. 2018 Jan;50(1):195-203. doi: 10.4143/crt.2016.376. Epub 2017 Mar 21.

255. Kim YS, Kim TJ, Lim HK, Rhim H, Jung SH, Ahn JH, Lee JW, Kim BG. Preservation of the endometrial enhancement after magnetic resonance imaging-guided high-intensity focused ultrasound ablation of submucosal uterine fibroids. Eur Radiol. 2017 Sep;27(9):3956-3965. doi: 10.1007/s00330-017-4765-4. Epub 2017 Feb 16.

256. Yang K, Park W, Huh SJ, Park BK, Kim CK, Kim BG, Bae DS, Lee JW. Parametrial Involvement on Magnetic Resonance Imaging Has No Effect on the Survival of Early-Stage Cervical Cancer Patients. Int J Gynecol Cancer. 2017 Mar;27(3):507-513. doi: 10.1097/IGC.0000000000000909

257. McGee J, Bookman M, Harter P, Marth C, McNeish I, Moore KN, Poveda A, Hilpert F, Hasegawa K, Bacon M, Gatsonis C, Brand A, Kridelka F, Berek J, Ottevanger N, Levy T, Silverberg S, Kim BG, Hirte H, Okamoto A, Stuart G, Ochiai K; participants of the 5th Ovarian Cancer Consensus Conference. Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors. Ann Oncol. 2017 Apr 1;28(4):702-710. doi: 10.1093/annonc/mdx010

258. Kang S, Nam JH, Bae DS, Kim JW, Kim MH, Chen X, No JH, Lee JM, Kim JH, Watari H, Kim SM, Kim SH, Seong SJ, Kim KT, Kim SC, Kim JH, Lim MC, Lee JY, Ryu SY, Yang B, Kim BG. Preoperative assessment of lymph node metastasis in endometrial cancer: A Korean Gynecologic Oncology Group study. Cancer. 2017 Jan 1;123(2):263-272. doi: 10.1002/cncr.30349. Epub 2016 Nov 7

259. Heo EJ, Cho YJ, Cho WC, Hong JE, Jeon HK, Oh DY, Choi YL, Song SY, Choi JJ, Bae DS, Lee YY, Choi CH, Kim TJ, Park WY, Kim BG, Lee JW. Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies. Cancer Res Treat. 2017 Oct;49(4):915-926. doi: 10.4143/crt.2016.322. Epub 2017 Jan 4

260. Song T, Kim MK, Jung YW, Yun BS, Seong SJ, Choi CH, Kim TJ, Lee JW, Kim BG, Bae DS. The role of appendectomy in patients with mucinous borderline ovarian tumors. Eur J Obstet Gynecol Reprod Biol. 2018 Jun 19;229:112-116. doi: 10.1016/j.ejogrb.2018.06.034. [Epub ahead of print]

261. Aoki Y, Ochiai K, Lim S, Aoki D, Kamiura S, Lin H, Katsumata N, Cha SD, Kim JH, Kim BG, Hirashima Y, Fujiwara K, Kim YT, Kim SM, Chung HH, Chang TC, Kamura T, Takizawa K, Takeuchi M, Kang SB. Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer. Br J Cancer. 2018 Aug 3. doi: 10.1038/s41416-018-0206-7. [Epub ahead of print

262. Choi HJ, Paik ES, Choi CH, Kim TJ, Lee YY, Lee JW, Bae DS, Kim BG. Response to Combination Chemotherapy With Paclitaxel/Ifosfamide/Platinum Versus Paclitaxel/Platinum for Patients With Metastatic, Recurrent, or Persistent Carcinoma of the Uterine Cervix: A Retrospective Analysis. Int J Gynecol Cancer. 2018 Sep;28(7):1333-1341. doi: 10.1097/IGC.0000000000001316.

263. Garland SM, Pitisuttithum P, Ngan HYS, Cho CH, Lee CY, Chen CA, Yang YC, Chu TY, Twu NF, Samakoses R, Takeuchi Y, Cheung TH, Kim SC, Huang LM, Kim BG, Kim YT, Kim KH, Song YS, Lalwani S, Kang JH, Sakamoto M, Ryu HS, Bhatla N, Yoshikawa H, Ellison MC, Han SR, Moeller E, Murata S, Ritter M, Sawata M, Shields C, Walia A, Perez G, Luxembourg A. Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries. J Infect Dis. 2018 Jun 5;218(1):95-108. doi: 10.1093/infdis/jiy133

264. Shin W, Lee HJ, Yang SJ, Paik ES, Choi HJ, Kim TJ, Choi CH, Lee JW, Bae DS, Kim BG. Retrospective study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer. Obstet Gynecol Sci. 2018 May;61(3):352-358. doi: 10.5468/ogs.2018.61.3.352. Epub 2018 May 9.

265. Lee HJ, Shin W, Jang YJ, Choi CH, Lee JW, Bae DS, Kim BG. Clinical characteristics and outcomes of placental site trophoblastic tumor: experience of single institution in Korea. Obstet Gynecol Sci. 2018 May;61(3):319-327. doi: 10.5468/ogs.2018.61.3.319. Epub 2018 Apr 27

266. Paik ES, Kim TJ, Choi CH, Kim BG, Bae DS, Lee JW. Clinical outcomes of patients with clear cell and endometrioid ovarian cancer arising from endometriosis. J Gynecol Oncol. 2018 Mar;29(2):e18. doi: 10.3802/jgo.2018.29.e18. Epub 2017 Dec 11.

267. Paik ES, Kim JH, Kim TJ, Lee JW, Kim BG, Bae DS, Choi CH. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer. J Gynecol Oncol. 2018 Jan;29(1):e13. doi: 10.3802/jgo.2018.29.e13.

268. Kim J, Chang Y, Kim TJ, Lee JW, Kim BG, Bae DS, Choi CH. Optimal cutoff age for predicting prognosis associated with serous epithelial ovarian cancer: what is the best age cutoff? J Gynecol Oncol. 2018 Oct 22. doi: 10.3802/jgo.2019.30.e11. [Epub ahead of print]

269. Song T, Kim MK, Jung YW, Yun BS, Seong SJ, Choi CH, Kim TJ, Lee JW, Kim BG, Bae DS. The role of appendectomy in patients with mucinous borderline ovarian tumors.. Eur J Obstet Gynecol Reprod Biol. 2018 Oct;229:112-116. doi: 10.1016/j.ejogrb.2018.06.034. Epub 2018 Jun 19

270. Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018 Oct 21. doi: 10.1056/NEJMoa1810858. [Epub ahead of print]

271. Lawrenson K, Song F, Hazelett DJ, Kar SP, Tyrer J, Phelan CM, Corona RI, Rodríguez-Malavé NI, Seo JH, Adler E, Coetzee SG, Segato F, Fonseca MAS, Amos CI, Carney ME, Chenevix-Trench G, Choi J, Doherty JA, Jia W, Jin GJ, Kim BG, Le ND, Lee J, Li L, Lim BK, Adenan NA, Mizuno M, Park B, Pearce CL, Shan K, Shi Y, Shu XO, Sieh W; Australian Ovarian Cancer Study Group, Thompson PJ, Wilkens LR, Wei Q, Woo YL, Yan L, Karlan BY, Freedman ML, Noushmehr H, Goode EL, Berchuck A, Sellers TA, Teo SH, Zheng W, Matsuo K, Park S, Chen K, Pharoah PDP, Gayther SA, Goodman MT. Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. Gynecol Oncol. 2019 May;153(2):343-355. doi: 10.1016/j.ygyno.2019.02.023. Epub 2019 Mar 19

272. Lee H, Hur S, Jang H, Lee IH, Sohn WY, Van Kriekinge G, Kim BG. Cost-Utility of a Two-Dose Human Papillomavirus Vaccination Programme Added to Cervical Cancer Screening Compared with Cervical Cancer Screening Alone in Korea. Asian Pac J Cancer Prev. 2019 Feb 26;20(2):425-435.

273. Kim J, Chang Y, Kim TJ, Lee JW, Kim BG, Bae DS, Choi CH. Optimal cutoff age for predicting prognosis associated with serous epithelial ovarian cancer: what is the best age cutoff? J Gynecol Oncol. 2019 Jan;30(1):e11. doi: 10.3802/jgo.2019.30.e11. Epub 2018 Oct 22.

274. Paik ES, Lee JW, Park JY, Kim JH, Kim M, Kim TJ, Choi CH, Kim BG, Bae DS, Seo SW. Prediction of survival outcomes in patients with epithelial ovarian cancer using machine learning methods. J Gynecol Oncol. 2019 Jul;30(4):e65. doi: 10.3802/jgo.2019.30.e65. Epub 2019 Mar 11.

275. Yarmolinsky J, Relton CL, Lophatananon A, Muir K, Menon U, Gentry-Maharaj A, Walther A, Zheng J, Fasching P, Zheng W, Yin Ling W, Park SK, Kim BG, Choi JY, Park B, Davey Smith G, Martin RM, Lewis SJ. Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis. PLoS Med. 2019 Aug 7;16(8):e1002893. doi: 10.1371/journal.pmed.1002893. eCollection 2019 Aug

276. Lee JY, Kim JW, Lim MC, Kim S, Kim HS, Choi CH, Yi JY, Park SY, Kim BG; KGOG investigators. A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D. J Gynecol Oncol. 2019 Nov;30(6):e112. doi: 10.3802/jgo.2019.30.e112

277. Lee YY, Cho YJ, Shin SW, Choi C, Ryu JY, Jeon HK, Choi JJ, Hwang JR, Choi CH, Kim TJ, Kim BG, Bae DS, Park W, Lee JW. Anti-Tumor Effects of Wee1 Kinase Inhibitor with Radiotherapy in Human Cervical Cancer. Sci Rep. 2019 Oct 28;9(1):15394. doi: 10.1038/s41598-019-51959-3

278. Lee JY, Yi JY, Kim HS, Lim J, Kim S, Nam BH, Kim HS, Kim JW, Choi CH, Kim BG; KGOG investigators. An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION. Jpn J Clin Oncol. 2019 Aug 1;49(8):789-792. doi: 10.1093/jjco/hyz085

279. Jeong SY, Park H, Kim MS, Kang JH, Paik ES, Lee YY, Kim TJ, Lee JW, Kim BG, Bae DS, Choi CH. Pretreatment Lymph Node Metastasis as a Prognostic Significance in Cervical Cancer: Comparison between Disease Status. Cancer Res Treat. 2019 Oct 29. doi: 10.4143/crt.2019.328. [Epub ahead of print]

280. Choi HJ, Lee YY, Sohn I, Kim YM, Kim JW, Kang S, Kim BG. Comparison of CA 125 alone and risk of ovarian malignancy algorithm (ROMA) in patients with adnexal mass: A multicenter study. Curr Probl Cancer. 2019 Nov 1:100508. doi: 10.1016/j.currproblcancer.2019.100508. [Epub ahead of print] Review.

281. Paik ES, Lee YJ, Lee JY, Shin W, Park SY, Kim SI, Kim JW, Choi CH, Kim BG. Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study. J Clin Med. 2019 Nov 8;8(11). pii: E1920. doi: 10.3390/jcm8111920.

282. Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer. N Engl J Med. 2019 Nov 14;381(20):1929-1939. doi: 10.1056/NEJMoa1902626.

283. Kim MS, Choi CH, Lee JW, Kim BG, Bae DS, Kim TJ. Comparison between Laparoendoscopic Single-Site and Conventional Laparoscopic Surgery in Mature Cystic Teratoma of the Ovary. Gynecol Minim Invasive Ther. 2019 Oct 24;8(4):155-159. doi: 10.4103/GMIT.GMIT_3_19. eCollection 2019 Oct-Dec.

284. Sa JK, Hwang JR, Cho YJ, Ryu JY, Choi JJ, Jeong SY, Kim J, Kim MS, Paik ES, Lee YY, Choi CH, Kim TJ, Kim BG, Bae DS, Lee Y, Her NG, Shin YJ, Cho HJ, Kim JY, Seo YJ, Koo H, Oh JW, Lee T, Kim HS, Song SY, Bae JS, Park WY, Han HD, Ahn HJ, Sood AK, Rabadan R, Lee JK, Nam DH, Lee JW. Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers. Genome Biol. 2019 Nov 26;20(1):253. doi: 10.1186/s13059-019-1848-3.

285. Jeong SY, Choi CH, Kim TJ, Lee JW, Kim BG, Bae DS, Lee YY. Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer. J Ovarian Res. 2019 Dec 31;13(1):1. doi: 10.1186/s13048-019-0602-5.

286. Choi CH, Choi HJ, Lee JW, Kang ES, Cho D, Park BK, Kim YM, Kim DY, Seo H, Park M, Kim W, Choi KY, Oh T, Kang CY, Kim BG. Phase I Study of a B Cell-Based and Monocyte-Based Immunotherapeutic Vaccine, BVAC-C in Human Papillomavirus Type 16- or 18-Positive Recurrent Cervical Cancer. J Clin Med. 2020 Jan 5;9(1). pii: E147. doi: 10.3390/jcm9010147

287. Choi HJ, Lee YY, Choi CH, Kim TJ, Lee JW, Bae JH, Bae DS, Kim BG. Triplet chemotherapy vs doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer. Curr Probl Cancer. 2020 Feb 12:100557. doi: 10.1016/j.currproblcancer.2020.100557. [Epub ahead of print]

288. Choi CH, Chung JY, Kang JH, Paik ES, Lee YY, Park W, Byeon SJ, Chung EJ, Kim BG, Hewitt SM, Bae DS. Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer. Gynecol Oncol. 2020 Feb 24. pii: S0090-8258(20)30153-0. doi: 10.1016/j.ygyno.2020.02.017. [Epub ahead of print]

289. Paik ES, Kim TH, Cho YJ, Ryu J, Choi JJ, Lee YY, Kim TJ, Choi CH, Kim WY, Sa JK, Lee JK, Kim BG, Bae DS, Han HD, Ahn HJ, Lee JW. Preclinical assessment of the VEGFR inhibitor axitinib as a therapeutic agent for epithelial ovarian cancer.Sci Rep. 2020 Mar 17;10(1):4904. doi: 10.1038/s41598-020-61871-w. PMID: 32184452

290. Kang M, Kim J, Kim TJ, Lee JW, Kim BG, Bae DS, Choi CH. Long-term outcomes of single-port laparoscopic myomectomy using a modified suture technique.Obstet Gynecol Sci. 2020 Mar;63(2):164-172. doi: 10.5468/ogs.2020.63.2.164. Epub 2020 Feb 12.PMID: 32206656

291. Cho M, Kim CJ, Hahm TS, Lee YY, Kim TJ, Lee JW, Kim BG, Bae DS, Choi CH. Combination of a pulmonary recruitment maneuver and intraperitoneal bupivacaine for the reduction of postoperative shoulder pain in gynecologic laparoscopy: a randomized, controlled trial.Obstet Gynecol Sci. 2020 Mar;63(2):187-194. doi: 10.5468/ogs.2020.63.2.187. Epub 2020 Feb 20.PMID: 32206659

292. Kim J, Chung JY, Hwang JR, Lee YY, Kim TJ, Lee JW, Kim BG, Bae DS, Choi CH, Hewitt SM. Identification of Candidate Genes Associated with Susceptibility to Ovarian Clear Cell Adenocarcinoma Using cis-eQTL Analysis.J Clin Med. 2020 Apr 16;9(4):1137. doi: 10.3390/jcm9041137.PMID: 32316112

293. Paik ES, Baek SH, Kang JH, Jeong SY, Kim MS, Kim WY, Lee YY, Choi CH, Lee JW, Kim BG, Bae DS, Kim TJ.. Comparison of Laparoscopy and Laparotomy for Para-Aortic Lymphadenectomy in Women With Presumed Stage I-II High-Risk Endometrial Cancer. Front Oncol. 2020 Apr 7;10:451. doi: 10.3389/fonc.2020.00451. eCollection 2020.PMID: 32318344

294. DiSilvestro P, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian CA, Bradley WH, Mathews CA, Liu J, Lowe ES, Bloomfield R, Moore KN. Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial.J Clin Oncol. 2020 Oct 20;38(30):3528-3537. doi: 10.1200/JCO.20.00799. Epub 2020 Aug 4. PMID: 32749942

295. Hwang S, Kim BG, Song SY, Kim HS. Ovarian Gynandroblastoma with a Juvenile Granulosa Cell Tumor Component in a Postmenopausal Woman.Diagnostics (Basel). 2020 Jul 30;10(8):537. doi: 10.3390/diagnostics10080537.PMID: 3275172

296. Kim HS, Park SY, Park CY, Kim YT, Kim BJ, Song YJ, Kim BG, Kim YB, Cho CH, Kim JH, Song YS. A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer. Br J Cancer. 2021 Jan;124(2):375-382. doi: 10.1038/s41416-020-01098-8. Epub 2020 Sep 30.PMID: 32994466

297. Kang JH, Noh JJ, Jeong SY, Shim JI, Lee YY, Choi CH, Lee JW, Kim BG, Bae DS, Kim HS, Kim TJ. Feasibility of Single-Port Access (SPA) Laparoscopy for Large Ovarian Tumor Suspected to Be Borderline Ovarian Tumor. Front Oncol. 2020 Sep 16;10:583515. doi: 10.3389/fonc.2020.583515. eCollection 2020.PMID: 33042851

298. Noh JJ, Kim MS, Cho YJ, Jeong SY, Lee YY, Ryu JY, Choi JJ, Bae I, Wu Z, Kim BG, Hwang JR, Lee JW. Anti-Cancer Activity of As4O6 and its Efficacy in a Series of Patient-Derived Xenografts for Human Cervical Cancer. Pharmaceutics. 2020 Oct 19;12(10):987. doi: 10.3390/pharmaceutics12100987.PMID: 33086573

299. Shin W, Noh JJ, Seo SS, Kang S, Choi CH, Park SY, Kim BG, Lim MC. Survival Effects of Cytoreductive Surgery for Refractory Patients after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer. Yonsei Med J. 2020 Nov;61(11):935-941. doi: 10.3349/ymj.2020.61.11.935.PMID: 33107236

300. Kang JH, Cho WK, Yeo HJ, Jeong SY, Noh JJ, Shim JI, Lee YY, Kim TJ, Lee JW, Kim BG, Bae DS, Park W, Choi CH. Prognostic Significance of Tumor Regression Rate during Concurrent Chemoradiotherapy in Locally Advanced Cervix Cancer: Analysis by Radiation Phase and Histologic Type. J Clin Med. 2020 Oct 28;9(11):3471. doi: 10.3390/jcm9113471.PMID: 33126569

301. Choi MC, Kim YM, Lee JW, Lee YJ, Suh DH, Lee SJ, Lee TS, Lee M, Park DC, Kim MK, Lee JM, Shim SH, Jeon S, Min KJ, Kim MK, Kim BW, Park JY, Kim BG, Kim DY, Kim MH, Kim HS, Lee JY. Real-World Experience of Pembrolizumab Monotherapy in Patients with Recurrent or Persistent Cervical Cancer: A Korean Multi-Center Retrospective Study (KGOG1041).Cancers (Basel). 2020 Oct 29;12(11):3188. doi: 10.3390/cancers12113188.PMID: 33138190

302. Youn JW, Hur SY, Woo JW, Kim YM, Lim MC, Park SY, Seo SS, No JH, Kim BG, Lee JK, Shin SJ, Kim K, Chaney MF, Choi YJ, Suh YS, Park JS, Sung YC. Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial. Lancet Oncol. 2020 Dec;21(12):1653-1660. doi: 10.1016/S1470-2045(20)30486-1.PMID: 33271094

303. Kim N, Park W, Cho WK, Bae DS, Kim BG, Lee JW, Kim TJ, Choi CH, Lee YY, Cho YS. Early Metabolic Response Assessed Using 18F-FDG-PET/CT for Image-Guided Intracavitary Brachytherapy Can Better Predict Treatment Outcomes in Patients with Cervical Cancer. Cancer Res Treat. 2021 Jul;53(3):803-812. doi: 10.4143/crt.2020.1251. Epub 2020 Dec 9.PMID: 33321566

304. Lee YJ, Lim MC, Kim BG, Ngoi NY, Choi CH, Park SY, Tan DS, Go Y, Lee JY. A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01). J Gynecol Oncol. 2021 Mar;32(2):e31. doi: 10.3802/jgo.2021.32.e31. Epub 2021 Jan 27.PMID: 33559413

305. Lee J, Kim HS, Kim K, Bae DS, Kim BG, Choi CH. Metabolic syndrome and persistent cervical human papillomavirus infection. Gynecol Oncol. 2021 May;161(2):559-564. doi: 10.1016/j.ygyno.2021.02.009. Epub 2021 Mar 4.PMID: 33676760

306. Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.Lancet Oncol. 2021 May;22(5):620-631. doi: 10.1016/S1470-2045(21)00073-5. Epub 2021 Mar 18.PMID: 33743851

307. Noh KW, Kim B, Choi CH, Kim TJ, Lee JW, Kim BG, Bae DS, Cho WK, Park W, Lee YY. Effect of Waiting Time from Pathological Diagnosis to Definitive Concurrent Chemoradiation for Cervical Cancer on Overall Survival. Cancer Res Treat. 2022 Jan;54(1):245-252. doi: 10.4143/crt.2021.023. Epub 2021 Apr 15.PMID: 33857364

308. Friedlander M, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Lisyanskaya A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley WH, Liu J, Mathews C, Selle F, Lortholary A, Lowe ES, Hettle R, Flood E, Parkhomenko E, DiSilvestro P. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. Lancet Oncol. 2021 May;22(5):632-642. doi: 10.1016/S1470-2045(21)00098-X. Epub 2021 Apr 13.PMID: 33862001

309. Jung J, Noh JJ, Choi CH, Kim TJ, Lee JW, Kim BG, Bae DS, Lee YY. Minimally-Invasive Versus Abdominal Hysterectomy for Endometrial Carcinoma With Glandular or Stromal Invasion of Cervix. Front Oncol. 2021 May 20;11:670214. doi: 10.3389/fonc.2021.670214. eCollection 2021.PMID: 34094966

310. Kim N, Park W, Cho WK, Bae DS, Kim BG, Lee JW, Choi CH, Kim TJ, Lee YY. Significance of serum CA125 level in surgically resected cervical adenocarcinoma with adverse features. J Gynecol Oncol. 2021 Sep;32(5):e72. doi: 10.3802/jgo.2021.32.e72. Epub 2021 May 18.PMID: 34132070

311. Noh JJ, Kim J, Paik ES, Kang JH, Jeong SY, Choi CH, Lee YY, Lee JW, Kim BG, Bae DS, Kim TJ. Single-port access (SPA) laparoscopic myomectomy with uterine artery ligation via a retroperitoneal approach is feasible in women with large uterine leiomyoma. Taiwan J Obstet Gynecol. 2021 Jul;60(4):752-757. doi: 10.1016/j.tjog.2021.05.029.PMID: 34247819

312. Jeong SY, Chung JY, Byeon SJ, Kim CJ, Lee YY, Kim TJ, Lee JW, Kim BG, Chae YL, Oh SY, Choi CH. Validation of Potential Protein Markers Predicting Chemoradiores istance in Early Cervical Cancer by Immunohistochemistry. Front Oncol. 2021 Jul 19;11:665595. doi: 10.3389/fonc.2021.665595. eCollection 2021.PMID: 34350111

313. Shin W, Noh JJ, Baek SH, Kim BG, Lim MC, Park SY. Real-world Experience of Niraparib in Newly-diagnosed Epithelial Ovarian Cancer. Anticancer Res. 2021 Sep;41(9):4603-4607. doi: 10.21873/anticanres.15273.PMID: 34475088

314. Paik ES, Heo EJ, Choi CH, Kim JH, Kim JW, Kim YM, Park SY, Lee JW, Kim JW, Kim BG. Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer. Cancer Sci. 2021 Dec;112(12):5055-5067. doi: 10.1111/cas.15166. Epub 2021 Oct 25.PMID: 34657357

315. Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley WH, Holmes E, Lowe ES, DiSilvestro P. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021 Dec;22(12):1721-1731. doi: 10.1016/S1470-2045(21)00531-3. Epub 2021 Oct 26.PMID: 34715071

316. Paik ES, Chang CS, Chae YL, Oh SY, Byeon SJ, Kim CJ, Lee YY, Kim TJ, Lee JW, Kim BG, Choi CH. Prognostic Relevance of BRCA1 Expression in Survival of Patients With Cervical Cancer. Front Oncol. 2021 Nov 8;11:770103. doi: 10.3389/fonc.2021.770103. eCollection 2021.PMID: 34820332

317. Park J, Lim MC, Lee JK, Jeong DH, Kim SI, Choi MC, Kim BG, Lee JY. A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial. J Gynecol Oncol. 2022 Mar;33(2):e12. doi: 10.3802/jgo.2022.33.e12. Epub 2021 Dec 6.PMID: 34910393

318. Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, Aben KKH, Adank MA, Agata S, Andrulis IL, Anton-Culver H, Antonenkova NN, Aravantinos G, Arun BK, Augustinsson A, Balmaña J, Bandera EV, Barkardottir RB, Barrowdale D, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Bjorge L, Black A, Bogdanova NV, Bonanni B, Borg A, Brenton JD, Budzilowska A, Butzow R, Buys SS, Cai H, Caligo MA, Campbell I, Cannioto R, Cassingham H, Chang-Claude J, Chanock SJ, Chen K, Chiew YE, Chung WK, Claes KBM, Colonna S; GEMO Study Collaborators; GC-HBOC Study Collaborators; EMBRACE Collaborators, Cook LS, Couch FJ, Daly MB, Dao F, Davies E, de la Hoya M, de Putter R, Dennis J, DePersia A, Devilee P, Diez O, Ding YC, Doherty JA, Domchek SM, Dörk T, du Bois A, Dürst M, Eccles DM, Eliassen HA, Engel C, Evans GD, Fasching PA, Flanagan JM, Fortner RT, Machackova E, Friedman E, Ganz PA, Garber J, Gensini F, Giles GG, Glendon G, Godwin AK, Goodman MT, Greene MH, Gronwald J; OPAL Study Group; AOCS Group, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TVO, Harris HR, Hartman M, Heitz F, Hildebrandt MAT, Høgdall E, Høgdall CK, Hopper JL, Huang RY, Huff C, Hulick PJ, Huntsman DG, Imyanitov EN; KConFab Investigators; HEBON Investigators, Isaacs C, Jakubowska A, James PA, Janavicius R, Jensen A, Johannsson OT, John EM, Jones ME, Kang D, Karlan BY, Karnezis A, Kelemen LE, Khusnutdinova E, Kiemeney LA, Kim BG, Kjaer SK, Komenaka I, Kupryjanczyk J, Kurian AW, Kwong A, Lambrechts D, Larson MC, Lazaro C, Le ND, Leslie G, Lester J, Lesueur F, Levine DA, Li L, Li J, Loud JT, Lu KH, Lubiński J, Mai PL, Manoukian S, Marks JR, Matsuno RK, Matsuo K, May T, McGuffog L, McLaughlin JR, McNeish IA, Mebirouk N, Menon U, Miller A, Milne RL, Minlikeeva A, Modugno F, Montagna M, Moysich KB, Munro E, Nathanson KL, Neuhausen SL, Nevanlinna H, Yie JNY, Nielsen HR, Nielsen FC, Nikitina-Zake L, Odunsi K, Offit K, Olah E, Olbrecht S, Olopade OI, Olson SH, Olsson H, Osorio A, Papi L, Park SK, Parsons MT, Pathak H, Pedersen IS, Peixoto A, Pejovic T, Perez-Segura P, Permuth JB, Peshkin B, Peterlongo P, Piskorz A, Prokofyeva D, Radice P, Rantala J, Riggan MJ, Risch HA, Rodriguez-Antona C, Ross E, Rossing MA, Runnebaum I, Sandler DP, Santamariña M, Soucy P, Schmutzler RK, Setiawan VW, Shan K, Sieh W, Simard J, Singer CF, Sokolenko AP, Song H, Southey MC, Steed H, Stoppa-Lyonnet D, Sutphen R, Swerdlow AJ, Tan YY, Teixeira MR, Teo SH, Terry KL, Terry MB; OCAC Consortium; CIMBA Consortium, Thomassen M, Thompson PJ, Thomsen LCV, Thull DL, Tischkowitz M, Titus L, Toland AE, Torres D, Trabert B, Travis R, Tung N, Tworoger SS, Valen E, van Altena AM, van der Hout AH, Van Nieuwenhuysen E, van Rensburg EJ, Vega A, Edwards DV, Vierkant RA, Wang F, Wappenschmidt B, Webb PM, Weinberg CR, Weitzel JN, Wentzensen N, White E, Whittemore AS, Winham SJ, Wolk A, Woo YL, Wu AH, Yan L, Yannoukakos D, Zavaglia KM, Zheng W, Ziogas A, Zorn KK, Kleibl Z, Easton D, Lawrenson K, DeFazio A, Sellers TA, Ramus SJ, Pearce CL, Monteiro AN, Cunningham J, Goode EL, Schildkraut JM, Berchuck A, Chenevix-Trench G, Gayther SA, Antoniou AC, Pharoah PDP. Polygenic risk modeling for prediction of epithelial ovarian cancer risk. Eur J Hum Genet. 2022 Mar;30(3):349-362. doi: 10.1038/s41431-021-00987-7. Epub 2022 Jan 14.PMID: 35027648

319. Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Ushijima K, Sakata J, Yonemori K, Kim YM, Guerra EM, Sanli UA, McCormack MM, Smith AD, Keefe S, Bird S, Dutta L, Orlowski RJ, Lorusso D; Study 309–KEYNOTE-775 Investigators. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. N Engl J Med. 2022 Feb 3;386(5):437-448. doi: 10.1056/NEJMoa2108330. Epub 2022 Jan 19.PMID: 35045221

320. Park J, Kim SI, Jeong SY, Kim Y, Bookman MA, Kim JW, Kim BG, Lee JY. Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study. Gynecol Oncol. 2022 Apr;165(1):97-104. doi: 10.1016/j.ygyno.2022.02.002. Epub 2022 Feb 10.PMID: 35153073

321. Lee JY, Kim BG, Kim JW, Lee JB, Park E, Joung JG, Kim S, Choi CH, Kim HS; Korean Gynecologic Oncology Group (KGOG) investigators. Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial. J Gynecol Oncol. 2022 Jul;33(4):e45. doi: 10.3802/jgo.2022.33.e45. Epub 2022 Mar 4.PMID: 35320892

322. Lim H, In Shim J, Park SJ, Noh J, Kim TM, Lee M, Choi CH, Chung HH, Kim TJ, Lee JW, Kim JW, Kim BG, Park NH, Song YS, Kim SY, Park SY, Kim HS, Lee YY. Impact of no residual disease on postoperative computed tomography on survival in patients with optimally debulked advanced high-grade serous ovarian cancer during upfront surgery. Gynecol Oncol. 2022 Jun;165(3):493-499. doi: 10.1016/j.ygyno.2022.03.014. Epub 2022 Mar 30.PMID: 35367074

323. Chang CS, Shim JI, Byeon SJ, Lee EJ, Lee YY, Kim TJ, Lee JW, Kim BG, Choi CH. Prognostic Significance of HER3 Expression in Patients with Cervical Cancer. Cancers (Basel). 2022 Apr 25;14(9):2139. doi: 10.3390/cancers14092139.PMID: 35565268

324. Goh JCH, Gourley C, Tan DSP, Nogueira-Rodrigues A, Elghazaly H, Edy Pierre M, Giornelli G, Kim BG, Morales-Vasquez F, Tyulyandina A. Optimizing treatment selection and sequencing decisions for first-line maintenance therapy of newly diagnosed advanced ovarian cancer. Gynecol Oncol Rep. 2022 Jun 17;42:101028. doi: 10.1016/j.gore.2022.101028. eCollection 2022 Aug.PMID: 35813356

325. Chang CS, Min JS, Song KH, Choi CH, Kim TJ, Lee JW, Kim BG, Lee YY. The Role of Conization before Radical Hysterectomy in Cervical Cancer including High Risk Factors of Recurrence: Propensity Score Matching. Cancers (Basel). 2022 Aug 10;14(16):3863. doi: 10.3390/cancers14163863.PMID: 36010857

326. Cho WK, Kim HS, Park W, Chang CS, Lee YY, Choi CH, Kim TJ, Lee JW, Kim BG. Predicting prognosis according to the updated WHO classification in patients with endocervical adenocarcinoma treated with surgery and radiotherapy. J Gynecol Oncol. 2022 Nov;33(6):e71. doi: 10.3802/jgo.2022.33.e71. Epub 2022 Aug 9.PMID: 36047374

327. DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, McNamara J, Lowe ES, Ah-See ML, Moore KN; SOLO1 Investigators. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRC A Mutation: The SOLO1/GOG 3004 Trial. J Clin Oncol. 2022 Sep 9:JCO2201549. doi: 10.1200/JCO.22.01549. Online ahead of print.PMID: 36082969

328. Meagher NS, Gorringe KL, Wakefield M, Bolithon A, Pang CNI, Chiu DS, Anglesio MS, Mallitt KA, Doherty JA, Harris HR, Schildkraut JM, Berchuck A, Cushing-Haugen KL, Chezar K, Chou A, Tan A, Alsop J, Barlow E, Beckmann MW, Boros J, Bowtell DDL; AOCS Group, Brand AH, Brenton JD, Campbell I, Cheasley D, Cohen J, Cybulski C, Elishaev E, Erber R, Farrell R, Fischer A, Fu Z, Gilks B, Gill AJ; Australian Pancreatic Genome Initiative, Gourley C, Grube M, Harnett PR, Hartmann A, Hettiaratchi A, Høgdall CK, Huzarski T, Jakubowska A, Jimenez-Linan M, Kennedy CJ, Kim BG, Kim JW, Kim JH, Klett K, Koziak JM, Lai T, Laslavic A, Lester J, Leung Y, Li N, Liauw W, Lim BWX, Linder A, Lubiński J, Mahale S, Mateoiu C, McInerny S, Menkiszak J, Minoo P, Mittelstadt S, Morris D, Orsulic S, Park SY, Pearce CL, Pearson JV, Pike MC, Quinn CM, Mohan GR, Rao J, Riggan MJ, Ruebner M, Salfinger S, Scott CL, Shah M, Steed H, Stewart CJR, Subramanian D, Sung S, Tang K, Timpson P, Ward RL, Wiedenhoefer R, Thorne H; kConFab Investigators, Cohen PA, Crowe P, Fasching PA, Gronwald J, Hawkins NJ, Høgdall E, Huntsman DG, James PA, Karlan BY, Kelemen LE, Kommoss S, Konecny GE, Modugno F, Park SK, Staebler A, Sundfeldt K, Wu AH, Talhouk A, Pharoah PDP, Anderson L, DeFazio A, Köbel M, Friedlander ML, Ramus SJ. Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes. Clin Cancer Res. 2022 Dec 15;28(24):5383-5395. doi: 10.1158/1078-0432.CCR-22-1206.PMID: 36222710

329. Kim JG, Park YJ, Do YS, Kim BG, Lee JW, Choi CH, Kim HC, Park KB, Hyun DH. Arteriovenous Malformation Associated with Intravenous Leiomyomatosis of the Uterus: Characteristic CT Findings and Treatment by Embolization and Surgery. J Vasc Interv Radiol. 2022 Oct 12:S1051-0443(22)01250-7. doi: 10.1016/j.jvir.2022.10.009. Online ahead of print.

330. Bae BK, Cho WK, Kim BG, Choi CH, Kim TJ, Lee YY, Lee JW, Park W. Patterns and risk factors of recurrence in low-risk early-stage cervical adenocarcinoma treated with surgery alone: implications on risk group stratification. Int J Gynecol Cance. 2022 Nov 11;ijgc-2022-003971. doi: 10.1136/ijgc-2022-003971

331. Chou HH, Fereday S, DeFazio A, Chang CL, Bowtell D, Hsu HC, Traficante N, Jeong SY, Cheng WF, Ariyarantne D; Australian Ovarian Cancer Study Group, Tung T, Rajadhyaksha V, Lee WH, Brown D, Kim BG. Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan. J Gynecol Oncol. 2022 Oct 5. doi: 10.3802/jgo.2023.34.e3. Online ahead of print.

332. Jeon J, Park BK, Lee JW, Choi CH, Lee YY, Kim TJ, Kim BG. Invisible cervical cancers on MRI: Can the type of histology (SCC versus non-SCC) influence surgical planning? Front Oncol. 2022 Dec 8;12:996516. doi: 10.3389/fonc.2022.996516. eCollection 2022.

333. Sung S, Hong Y, Kim BG, Choi JY, Kim JW, Park SY, Kim JH, Kim YM, Lee JM, Kim TJ, Park SK. Stratifying the risk of ovarian cancer incidence by histologic subtypes in the Korean Epithelial Ovarian Cancer Study (Ko-EVE). Cancer Med 2023 Apr;12(7):8742-8753. doi: 10.1002/cam4.5612. Epub 2023 Feb 15.

334. Tan D, Fujiwara N, Fujiwara K, Beale P, Kim JW, Ng J, Kim SI, Evans A, Kim BG; Asia-Pacific Gynecologic Oncology Trials Group (APGOT). The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women's cancer research organization. J Gynecol Oncol . 2023 Mar;34(2):e33. doi: 10.3802/jgo.2023.34.e33.

335. Tan D, Fujiwara N, Fujiwara K, Beale P, Kim JW, Ng J, Kim SI, Evans A, Kim BG; Asia-Pacific Gynecologic Oncology Trials Group (APGOT). The Asia-Pacific Gynecologic Oncology Trials Group (APGOT): building a Pan-Asian and Oceania women's cancer research organization. Int J Gynecol Cancer 2023 Apr 3;33(4):628-630. doi: 10.1136/ijgc-2022-004236.

336. Chang CS, Lai YL, Choi CH, Kim TJ, Lee JW, Kim BG, Cheng WF, Chen YL, Lee YY. Comparison of Minimally Invasive and Open Surgery for the Treatment of Endometrial Cancer with a High Risk of Recurrence: A Propensity Score Matching Study in Korea and Taiwan. Ann Surg Oncol . 2023 Oct;30(11):6855-6864. doi: 10.1245/s10434-023-13695-x. Epub 2023 Jun 29

337. im YN, Joung JG, Park E, Kim JW, Lee JB, Lim J, Kim S, Choi CH, Kim HS, Chung J, Kim BG, Lee JY. Randomized, two-arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045. Int J Cancer . 2023 Dec 15;153(12):2032-2044. doi: 10.1002/ijc.34696. Epub 2023 Aug 21.

338. Kim YN, Park B, Kim JW, Kim BG, Kim SW, Kim HS, Choi CH, Lim MC, Yl Ngoi N, Sp Tan D, Lee JY. Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4. Nat Commun . 2023 Sep 6;14(1):5476. doi: 10.1038/s41467-023-40829-2.

339. Park J, Lee JB, Lim MC, Kim BG, Kim JW, Kim S, Choi CH, Kim HS, Park SY, Lee JY; KGOG investigators. Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D. J Immunother Cancer. 2023 Oct;11(10):e007444. doi: 10.1136/jitc-2023-007444.

340. Na J, Chung YE, Jang IY, Lee YY, Kim TJ, Lee JW, Kim BG, Chang CS, Choi CH. Advantages of laparoscopy in gynecologic surgery in elderly patients. Obstet Gynecol Sci

. 2024 Mar;67(2):243-252. doi: 10.5468/ogs.23238. Epub 2023 Dec 6

341. Kim SI, Joung JG, Kim YN, Park J, Park E, Kim JW, Lee S, Lee JB, Kim S, Choi CH, Kim HS, Lim J, Chung J, Kim BG, Lee JY. Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial. Gynecol Oncol . 2024 Mar:182:7-14. doi: 10.1016/j.ygyno.2023.12.029. Epub 2024 Jan 20.

342. Bae BK, Bae H, Cho WK, Kim BG, Choi CH, Kim TJ, Lee YY, Lee JW, Kim HS, Park W. Risk Factors Affecting Clinical Outcomes of Low-risk Early-stage Human Papillomavirus-Associated Endocervical Adenocarcinoma Treated by Surgery Alone: Application of Silva Pattern. Int J Gynecol Pathol . 2024 Sep 1;43(5):447-456. doi: 10.1097/PGP.0000000000001007. Epub 2024 Jan 31

343. Yonemori K, Fujiwara K, Hasegawa K, Yunokawa M, Ushijima K, Suzuki S, Shikama A, Minobe S, Usami T, Kim JW, Kim BG, Wang PH, Chang TC, Yamamoto K, Han S, McKenzie J, Orlowski RJ, Miura T, Makker V, Man Kim Y. Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer. J Gynecol Oncol . 2024 Mar;35(2):e40. doi: 10.3802/jgo.2024.35.e40. Epub 2024 Jan 19.

344. Kim WJ, Noh JJ, Bang YJ, Yang MY, Kim JH, Park CH, Song HJ, Kim JM, Choi CH, Kim TJ, Lee JW, Kim BG, Min JJ, Kim CS, Hahm TS, Lee YY. Initial experience with the enhanced recovery after surgery (ERAS) protocols in gynecologic surgery at an urban academic tertiary medical center. Gland Surg . 2024 Jan 29;13(1):19-31. doi: 10.21037/gs-23-249. Epub 2024 Jan 25

345. Kim WJ, Choi BR, Noh JJ, Lee YY, Kim TJ, Lee JW, Kim BG, Choi CH. Comparison of RNA-Seq and microarray in the prediction of protein expression and survival prediction. Front Genet . 2024 Feb 23:15:1342021. doi: 10.3389/fgene.2024.1342021. eCollection 2024

346. Choi CH, Lee JW, Bae DS, Kang ES, Cho D, Kim YM, Kim K, Kim JW, Kim HS, Kim YT, Lee JY, Lim MC, Oh T, Song B, Jeon I, Park M, Kim WH, Kang CY, Kim BG. Efficacy and safety of BVAC-C in HPV type 16- or 18-positive cervical carcinoma who failed 1st platinum-based chemotherapy: a phase I/IIa study. Front Immunol . 2024 Mar 28:15:1371353. doi: 10.3389/fimmu.2024.1371353. eCollection 2024

347. Jang DH, Lee HG, Lee B, Kang S, Kim JH, Kim BG, Kim JW, Kim MH, Chen X, No JH, Lee JM, Kim JH, Watari H, Kim SM, Kim SH, Seong SJ, Jeong DH, Kim YH. Prediction of final pathology depending on preoperative myometrial invasion and grade assessment in low-risk endometrial cancer patients: A Korean Gynecologic Oncology Group ancillary study. PLoS One

. 2024 Jun 27;19(6):e0305360. doi: 10.1371/journal.pone.0305360. eCollection 2024.

348. Vergote I, González-Martín A, Fujiwara K, Kalbacher E, Bagaméri A, Ghamande S, Lee JY, Banerjee S, Maluf FC, Lorusso D, Yonemori K, Van Nieuwenhuysen E, Manso L, Woelber L, Westermann A, Covens A, Hasegawa K, Kim BG, Raimondo M, Bjurberg M, Cruz FM, Angelergues A, Cibula D, Barraclough L, Oaknin A, Gennigens C, Nicacio L, Teng MSL, Whalley E, Soumaoro I, Slomovitz BM; innovaTV 301/ENGOT-cx12/GOG-3057 Collaborators. Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer. N Engl J Med . 2024 Jul 4;391(1):44-55. doi: 10.1056/NEJMoa2313811

349. Birrer M, Li G, Yunokawa M, Lee JY, Kim BG, Oppermann CP, Zhou Q, Nishio S, Okamoto A, Wu X, Mileshkin L, Oaknin A, Ray-Coquard I, Hasegawa K, Jehl G, Vugmeyster Y, Zhang S, Bajars M, Yonemori K. Bintrafusp Alfa for Recurrent or Metastatic Cervical Cancer After Platinum Failure: A Nonrandomized Controlled Trial. JAMA Oncol . 2024 Sep 1;10(9):1204-1211. doi: 10.1001/jamaoncol.2024.2145

350. Min KJ, Kim NK, Song JY, Choi MC, Lee SW, Lee KH, Kim MK, Kang S, Choi CH, Lee JW, Lee EJ, Eom KY, Kim SW, Cho H, Lee SJ, Lim MC, Bae J, Yoo CW, Kim K, Kim DY, Lee C, Ryu SY, Jeon S, Kim JW, Nam BH, Kang SB, Kim KT, Nam JH, Kim BG, Kim YM, Kim JH. From the Beginning of the Korean Gynecologic Oncology Group to the Present and Next Steps. Cancers (Basel). 2024 Oct 9;16(19):3422. doi: 10.3390/cancers16193422

352. Jung-Yun Lee 1, David Tan 2 3, Isabelle Ray-Coquard 4, Jung Bok Lee 5, Byoung Gie Kim 6, Els Van Nieuwenhuysen 7, Ruby Yun-Ju Huang 8, Ka Yu Tse 9, Antonio González-Martin 10, Clare Scott 11, Kosei Hasegawa 12, Katie Wilkinson 13, Eun Yeong Yang 14, Stephanie Lheureux 15, Rebecca Kristeleit. Phase II randomized study of dostarlimab alone or with bevacizumab versus non-platinum chemotherapy in recurrent gynecological clear cell carcinoma (DOVE/APGOT-OV7/ENGOT-ov80). J Gynecol Oncol . 2025 Jan;36(1):e51. doi: 10.3802/jgo.2025.36.e51. Epub 2024 Dec 16

353. Lim MC, Choi YJ, Hur SY, Kim YM, No JH, Kim BG, Cho CH, Kim SH, Jeong DH, Lee JK, Kim JH, Choi YJ, Woo JW, Sung YC, Park JS. GX-188 DNA vaccine plus pembrolizumab in HPV 16- and/or 18-positive recurrent or advance cervical cancer: a phase 2 trial. EClinicalMedicine . 2024 Jul 13:74:102716. doi: 10.1016/j.eclinm.2024.102716. eCollection 2024 Aug

354. Park J, Joung JG, Lim MC, Lee J, Kim BG, Kim JW, Shin SJ, Kim S, Park E, Choi CH, Kim HS, Park SY, Lee JY. Neoadjuvant Chemotherapy with Dual Immune Checkpoint Inhibitors for Advanced-Stage Ovarian Cancer: Final Analysis of TRU-D Phase II Nonrandomized Clinical Trial. Clin Cancer Res . 2025 Mar 5. doi: 10.1158/1078-0432.CCR-24-3753. Online ahead of print

355. Kim JC, Park J, Lee YJ, Nam EJ, Kim SW, Kim SH, Kim YT, Kim SI, Kim JW, Kim BG, Lee JY. Efficacy of Chemotherapy Following Prior PARP-Inhibitor Treatment in Patients with Ovarian Cancer. Cancer Res Treat. 2025 Mar 19. doi: 10.4143/crt.2024.1202. Online ahead of print

356. Baek JY, Kim HS, Cho WK, Kim BG, Lee JW, Choi CH, Kim TJ, Lee YY, Park W. Significance of HPV status on tumor response and treatment outcomes in endocervical adenocarcinoma treated with definitive chemoradiotherapy: a retrospective study. J Gynecol Oncol . 2025 Mar 20. doi: 10.3802/jgo.2025.36.e92. Online ahead of print

357. Wang PH, Yang ST, Kim BG. The frontiers in gynecologic cancer management: Exploring the new hope to manage women with endometrial cancer by immunochemotherapy.

Taiwan J Obstet Gynecol. 2025 May;64(3):404-406. doi: 10.1016/j.tjog.2025.03.001.

358. Wang PH, Chen JR, Kim BG. The new hope to manage women with mismatch repair proficient endometrial cancer. Taiwan J Obstet Gynecol. 2025 May;64(3):410-412. doi: 10.1016/j.tjog.2025.03.002.

359. Olawaiye AB, Gladieff L, O'Malley DM, Kim JW, Garbaos G, Salutari V, Gilbert L, Mileshkin L, Devaux A, Hopp E, Lee YJ, Oaknin A, Scaranti M, Kim BG, Colombo N, McCollum ME, Diakos C, Clamp A, Leiser AL, Balázs B, Monk BJ, Scandurra G, McClung E, Kaczmarek E, Slomovitz B, De La Cueva H, de Carvalho Calabrich AF, Cassani C, You B, Van Gorp T, Churruca C, Caruso G, Nicum S, Bagaméri A, Artioli G, Bodnar L, Kang S, Vergote I, Kesner-Hays A, Pashova HI, Pai SG, Tudor IC, Jubb AM, Lorusso D. Relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): an open-label, randomised, controlled, phase 3 trial. Lancet, 2025 Jun 2:S0140-6736(25)01040-2. doi: 10.1016/S0140-6736(25)01040-2.

기타(관심분야 등)

2026-10월 진료일정

이전달 다음달

10 월

구분	목 01	금 02	토 03	일 04	월 05	화 06	수 07	목 08	금 09	토 10	일 11	월 12	화 13	수 14	목 15	금 16	토 17	일 18	월 19	화 20	수 21	목 22	금 23	토 24	일 25	월 26	화 27	수 28	목 29	금 30	토 31
오전
오후

외래